

(12) United States Patent

Lamego et al.

(54) MULTI-WAVELENGTH PHYSIOLOGICAL **MONITOR**

Applicant: Cercacor Laboratories, Inc., Irvine, CA

Inventors: Marcelo M. Lamego, Irvine, CA (US); Mohamed Diab, Mission Viejo, CA (US); Walter M. Weber, Laguna Hills, CA (US); Ammar Al-Ali, Tustin, CA

(US)

(73) Assignee: MASIMO CORPORATION, Irvine,

CA (US)

Subject to any disclaimer, the term of this (*) Notice:

patent is extended or adjusted under 35

(US); Joe Kiani, Laguna Niguel, CA

U.S.C. 154(b) by 360 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 13/862,266

(22)Filed: Apr. 12, 2013

Prior Publication Data (65)

US 2013/0338461 A1 Dec. 19, 2013

Related U.S. Application Data

- (63) Continuation of application No. 12/045,309, filed on Mar. 10, 2008, now Pat. No. 8,423,106, which is a continuation of application No. 11/139,291, filed on May 27, 2005, now Pat. No. 7,343,186.
- (60) Provisional application No. 60/586,069, filed on Jul. 7, 2004.
- (51) Int. Cl. A61B 5/1455 (2006.01)(2006.01)A61B 5/00

(Continued)

(52) U.S. Cl. CPC A61B 5/14552 (2013.01); A61B 5/0205 (2013.01); A61B 5/1495 (2013.01);

(Continued)

(45) **Date of Patent:**

*May 17, 2016

US 9,339,220 B2

Field of Classification Search

(10) **Patent No.:**

CPC .. A61B 5/1455; A61B 5/14551; A61B 5/145; A61B 5/14552

USPC 600/310, 322, 323, 336, 340, 473, 476; 356/41

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

3,638,640 A 2/1972 Shaw 11/1975 Lubbers et al. 3,922,088 A

(Continued)

FOREIGN PATENT DOCUMENTS

1 778 072 5/2007 EP JP 06-178767 6/1994

(Continued)

OTHER PUBLICATIONS

Jan. 25, 2011 Office Action for Japanese Patent Application No. 2007-520308 filed on Jun. 6, 2005.


(Continued)

Primary Examiner — Eric Winakur Assistant Examiner — Chu Chuan (JJ) Liu (74) Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear, LLP

ABSTRACT

A physiological monitor for determining blood oxygen saturation of a medical patient includes a sensor, a signal processor and a display. The sensor includes at least three light emitting diodes. Each light emitting diode is adapted to emit light of a different wavelength. The sensor also includes a detector, where the detector is adapted to receive light from the three light emitting diodes after being attenuated by tissue. The detector generates an output signal based at least in part upon the received light. The signal processor determines blood oxygen saturation based at least upon the output signal, and the display provides an indication of the blood oxygen saturation.

18 Claims, 12 Drawing Sheets



US 9,339,220 B2

Page 2


(51)	T 4 60			-	022 (10		11/1000	G 1
(51)	Int. Cl.				,833,618			Caro et al.
	G01N 21/31		(2006.01)		,860,919			Kiani-Azarbayjany et al.
	A61B 5/0205		(2006.01)		,890,929			Mills et al.
					,904,654			Wohltmann et al.
	A61B 5/1495		(2006.01)		5,919,134		7/1999	
	A61B 5/024		(2006.01)		,934,925			Tobler et al.
	G01N 21/35		(2014.01)		,940,182			Lepper, Jr. et al.
	G01N 21/359		(2014.01)		,995,855			Kiani et al.
(52)	U.S. Cl.		(====)		,997,343			Mills et al.
(52)					,002,952			Diab et al.
			14551 (2013.01); A61B 5/6826		,011,986			Diab et al.
	(2013.0	(1); A61E	3 5/6838 (2013.01); A61B 5/72		,027,452			Flaherty et al.
	(20	013.01);	G01N 21/314 (2013.01); A61B		5,036,642			Diab et al.
			13.01); <i>G01N 21/35</i> (2013.01);		,045,509			Caro et al.
		,	59 (2013.01); G01N 2201/0627		0,067,462			Diab et al.
	00				5,081,735			Diab et al.
		(2013.)	01); <i>G01N 2201/129</i> (2013.01)		,088,607			Diab et al.
					5,110,522			Lepper, Jr. et al.
(56)		Referen	ces Cited		5,124,597			Shehada et al.
					5,128,521			Marro et al.
	U.S. 1	PATENT	DOCUMENTS		5,129,675 5,144,868		10/2000 11/2000	
	4,114,604 A	9/1978	Shaw et al.		5,151,516 5,152,754			Kiani-Azarbayjany et al. Gerhardt et al.
	4,623,248 A		Sperinde		5,152,754			Diab et al.
	4,714,341 A		Hamaguri et al.		5,163,715			Larsen et al.
	4,854,699 A		Edgar, Jr.		,165,005			Mills et al.
	4,913,150 A		Cheung et al.		5,184,521			Coffin, IV et al.
	4,960,128 A		Gordon et al.		5,206,830			Diab et al.
	4,964,408 A	10/1990	Hink et al.		,229,856			Diab et al.
	5,041,187 A	8/1991	Hink et al.		5,232,609			Snyder et al.
	5,069,213 A	12/1991	Polczynski		5,236,047			Malin et al.
	5,163,438 A	11/1992	Gordon et al.		5,236,872			Diab et al.
	5,222,495 A	6/1993	Clarke et al.		5,241,683			Macklem et al.
	5,319,355 A	6/1994	Russek		5,253,097			Aronow et al.
	5,337,744 A	8/1994	Branigan		5,256,523			Diab et al.
	5,341,805 A		Stavridi et al.					
	5,355,880 A	10/1994	Thomas et al.		,263,222			Diab et al.
	D353,195 S		Savage et al.		5,278,522			Lepper, Jr. et al. Tobler et al.
	D353,196 S		Savage et al.		5,280,213			
	5,377,676 A		Vari et al.		,285,896			Tobler et al.
	5,413,100 A	5/1995	Barthelemy et al.		,301,493			Marro et al.
	D359,546 S		Savage et al.		,317,627			Ennen et al.
	5,431,170 A		Mathews		,321,100		11/2001	
	D361,840 S		Savage et al.		5,325,761		12/2001	
	D362,063 S		Savage et al.		,334,065			Al-Ali et al.
	5,452,717 A		Branigan et al.		5,343,224		1/2002	
	D363,120 S		Savage et al.		5,349,228		2/2002	Kiani et al.
	5,456,252 A		Vari et al.	6	,360,114	В1	3/2002	Diab et al.
	5,479,934 A	1/1996		6	,368,283	В1	4/2002	Xu et al.
	5,482,036 A		Diab et al.	6	,371,921	B1	4/2002	Caro et al.
	5,490,505 A		Diab et al.	6	,377,829	В1	4/2002	Al-Ali
	5,494,043 A		O'Sullivan et al.	6	,388,240	B2	5/2002	Schulz et al.
	5,533,511 A 5,534,851 A		Kaspari et al.	6	,397,091	B2	5/2002	Diab et al.
			Russek Savage et al.	6	,430,437	B1	8/2002	Marro
	5,561,275 A 5,562,002 A	10/1996		6	,430,525	В1	8/2002	Weber et al.
	5,590,649 A		Caro et al.	6	,463,311	B1	10/2002	Diab
	5,602,924 A		Durand et al.		,470,199			Kopotic et al.
	5,632,272 A		Diab et al.		,501,975			Diab et al.
	5,632,273 A		Suzuki	6	,505,059	В1		Kollias et al.
	5,638,816 A		Kiani-Azarbayjany et al.		,515,273		2/2003	
	5,638,818 A		Diab et al.		,519,487		2/2003	
	5,645,440 A		Tobler et al.		,525,386			Mills et al.
	5,685,299 A		Diab et al.		5,526,300			Kiani et al.
	5,720,284 A		Aoyagi et al.		5,541,756			Schulz et al.
	D393,830 S	4/1998	Tobler et al.		,542,764			Al-Ali et al.
	5,743,262 A	4/1998	Lepper, Jr. et al.		5,580,086			Schulz et al.
	5,755,226 A		Carim et al.		5.584.336			Ali et al.
	5,758,644 A		Diab et al.		5.595.316			Cybulski et al.
	5,760,910 A	6/1998	Lepper, Jr. et al.		5,597,932			Tian et al.
	5,769,785 A	6/1998	Diab et al.					
	5,772,589 A	6/1998	Bernreuter		5,597,933			Kiani et al.
	5,782,756 A	7/1998	Mannheimer		,606,511			Ali et al.
	5,782,757 A		Diab et al.		5,632,181			Flaherty et al.
	5,785,659 A		Caro et al.		,639,668			Trepagnier
	5,791,347 A		Flaherty et al.		,640,116		10/2003	
	5,810,734 A		Caro et al.		,643,530			Diab et al.
	5,823,950 A		Diab et al.		,650,917			Diab et al.
	5,830,131 A	11/1998	Caro et al.	6	,654,624	B2	11/2003	Diab et al.


US 9,339,220 B2 Page 3

U.S. PATENT DOCUMENTS 7,254,438 B2 8,2007 Schuman eral. 6,658,276 B2 12/2008 Kinal et al. 7,254,438 B2 8,2007 Ma-Nai et al. 7,274,435 B2 9,2007 Ma-Nai et al. 7,274,275 B2 9,2007 Ma-Nai et al. 7,280,888 B2 10,2004 Ma-Nai et al. 7,280,888 B2 10,2004 Ma-Nai et al. 7,280,888 B2 10,2007 Ma-Nai et al. 7,280,888 B2 12,2008 Mills et al. 7,280,888 B2 12,2008 Ma-Nai et al. 7,280,889 B2 12,2008 Ma-Nai et al. 7,280,888 B2 12,2008	(56) R	eferen	ces Cited	7,245,953		7/2007	
6,658,276 B2 122003 Kinal et al. 7,254,433 B2 82007 Schulz et al. 6,661,161 B1 122003 Lanzo et al. 7,274,225 B2 92007 Al-Ali et al. 6,678,543 B2 12000 Al-Ali et al. D738,268 B2 92007 Al-Ali et al. 6,684,093 B2 12000 Al-Ali et al. 7,289,383 D2 102007 Al-Ali et al. 6,697,675 B2 22004 Al-Ali 7,295,866 B2 112007 Al-Ali et al. 7,328,693 B1 112007 Al-Ali et al. 7,328,693 B1 12000 Al-Ali et al. 7,328,693 B1 12007 Al-Ali et al. 7,328,693 B2 <td>II S PA</td> <td>TENT</td> <td>DOCUMENTS</td> <td></td> <td></td> <td></td> <td></td>	II S PA	TENT	DOCUMENTS				
Content	0.5. TA	112111	DOCOMENTS			8/2007	Diab et al.
6-671,531 B2 12,2003 Al-Ali et al. 1,274,955 B2 9,2007 Klani et al. 6-678,543 B2 12,0004 Diab et al. 7,280,858 B2 10,2007 Al-Ali et al. 6-684,000 B2 12,0004 Al-Ali et al. 7,280,858 B2 11,2007 Al-Ali et al. 6-684,001 B2 12,0004 Al-Ali et al. 7,280,858 B2 11,2007 Al-Ali et al. 6-697,656 B1 22,0004 Al-Ali et al. 7,280,858 B2 11,2007 De Felice et al. 6-697,656 B1 22,0004 Al-Ali et al. 7,280,858 B2 11,2007 De Felice et al. 6-697,656 B1 22,0004 Al-Ali et al. 7,280,858 B2 11,2007 De Felice et al. 7,280,858 B2 11,2007 De Felice et al. 7,280,858 B2 11,2008 Mills et al. 8,280,470 B1 22,0004 Mills et al. 7,280,858 B2 12,0005 Mills et al. 7,280,858 B2 12,0		2/2003	Kianl et al.				
Control Cont							
6.684,090 B2 172004 Alci at 1. 7.289,855 B2 10,2007 Alci at 1. 6.684,091 B2 172004 Parker 7.292,883 B2 10,2007 Mansfield et al. 6.684,091 B2 172004 Parker 7.292,883 B2 10,2007 Mansfield et al. 6.697,657 B1 2,2004 Alci at 1. 7282,885 B2 10,2007 Mansfield et al. 6.697,657 B1 2,2004 Alci at 1. 7282,885 B2 10,2007 Mansfield et al. 6.697,657 B1 2,2004 Malci at 1. 7282,885 B2 10,2007 Mansfield et al. 6.697,658 B1 2,2004 Malci at 1. 7382,784 B2 2,2008 Malci et al. 7382,840 B2 2,2008 Malci at 1. 7482,878 B2 3,2008 Manon et al. 6.714,801 B1 3,2004 Rouss 7.434,158 B2 3,2008 Manon et al. 6.714,801 B1 3,2004 Malci at 1. 7382,186 B2 3,2008 Manon et al. 6.714,801 B2 3,2004 Malci at 1. 7382,181 B2 2,2008 Malci at 1. 7482,181 B2 2,2009 Malci at 1. 7482,181 B2 2,2009 Malci at 1. 7482,181 B2 2,2009 Malci at 1. 74				, ,			
6.699,656 Bl 22004 Al-Ali 7.292,866 B2 112007 De Felice et al.							
Copyright Copy							
Copp. Copp							
RE38.476 E 3.2004 Diab et al. 7.340,287 B2 3.2008 Mason et al. 6.691,480 B1 3.2004 Diab et al. 7.341,559 B2 3.2008 Saluego et al. 6.711,425 B1 3.2004 Reuss 7.343,186 B2 3.2008 Lanego et al. 7.345,186 B2 3.2008 Lanego et al. 7.345,186 B2 3.2004 LaNei et al. 7.355,512 B1 4.2008 LaNei et al. 7.355,512 B1 4.2008 Al-Ali et al. 7.355,512 B1 4.2008 Al-Ali et al. 7.371,981 B2 5.2008 Al-Ali et al. 7.371,981 B2 5.2008 Al-Ali et al. 7.371,985 B2 5.2008 Al-Ali et al. 7.373,193 B2 5.2008 Al-Ali et al. 7.377,794 B2 5.2008 Al-Ali et al. 7.378,000 B2 5.2008 Al-Ali et al. 7.							
6,690,194 B1 3,2004 Plab et al. 7,341,559 B2 3,2008 Schulz et al. 6,714,804 B2 3,2004 Al-Ali et al. D566,282 5 4,2004 Al-Ali et al. D566,282 5 4,2004 Al-Ali et al. 7,355,126 B1 4,2008 Al-Ali et al. 7,355,126 B1 4,2009 Al-Ali et al. 7,355,126 B1 4,2004 Parker 7,371,981 B2 5,2008 Al-Ali et al. 6,725,676 B2 4,2004 Al-Ali 7,373,139 B2 5,2008 Al-Ali et al. 6,725,676 B2 4,2004 Al-Ali 7,373,139 B2 5,2008 Al-Ali et al. 6,735,640 B2 6,726,660 B3 8,72004 Al-Ali 7,376,979 B3 5,2008 Al-Ali et al. 7,376,979 B2 5,2008 Al-Ali et al. 7,476,979 B2 6,726,970 Al-Ali 7,478,478 B2 10,2008 Al-Ali et al. 7,478,4							
6,711,425 B1 3/2004 Al-Ali et al. D566,282 S 4/2008 Al-Ali et al. Ali et al. C74,1582 B1 4/2008 Al-Ali et al. Ali et al. C74,1582 B1 4/2008 Al-Ali et al. Ali et al. C74,1582 B1 4/2004 Al-Ali et al. C74,1582 B1 4/2004 Al-Ali et al. C74,1582 B1 4/2004 Al-Ali et al. C74,1586 B2 4/2004 Al-Ali et al. C74,1586 B2 5/2008 Al-Ali et al. C74,1586 B2 5/2008 Al-Ali et al. C74,1596 B2 5/2008 Al-Ali et al. C74,						3/2008	Schulz et al.
REISS-892 E 4/2004 Diab et al. 7,355,512 B1 4/2008 Schurman 6/21,588 B1 4/2004 Perpagnier et al. 7,371,981 B2 5/2008 Al-Ali et al. 6/225,578 24/2004 Al-Ali 7,373,199 B2 5/2008 Al-Ali et al. 7,373,199 B2 5/2008 Al-Ali et al. 6/278,560 B2 4/2004 Al-Ali 7,373,199 B2 5/2008 Al-Ali et al. 6/278,560 B2 4/2004 Diab et al. 7,373,199 B2 5/2008 Al-Ali et al. 6/276,607 B2 5/2009 Diab et al. 7,377,799 B2 5/2008 Al-Ali et al. 6/276,067 B2 6/2004 Diab et al. 7,377,799 B2 5/2008 Al-Ali et al. 6/270,028 B1 8/2004 Al-Ali 4.1 7,377,799 B2 5/2008 Al-Ali et al. 6/270,028 B1 8/2004 Al-Ali 4.1 7,378,09 B2 5/2008 Al-Ali et al. 6/270,2300 B1 9/2004 Diab et al. 7,488,683 B2 1/2009 Diab et al. 7,488,683 B2 1/2009 Diab et al. 7,488,683 B2 1/2009 Diab et al. 7,440,787 B2 1/2008 Diab et al. 6.825,641 B2 1/2004 Diab et al. 7,467,002 B2 1/2008 Diab et al. 6.825,641 B2 1/2004 Diab et al. 7,467,002 B2 1/2008 Diab et al. 6.830,718 B2 1/2009 Diab et al. 7,467,001 B2 1/2009 Diab et al. 6.830,788 B2 2/2005 Diab et al. 6.850,788 B2 2/2005 Diab et al.							
6,721.582 B2 42004 Tepagnier et al. 7,356,365 B2 42008 Schurman 6,725.075 B1 42004 Parker 7,371.981 B2 5/2008 Al-Ali et al. 7,373.194 B2 5/2008 Schurman 6,765,660 B2 6/2004 Diab et al. 7,377.794 B2 5/2008 Diab et al. 7,377.794 B2 5/2008 Diab et al. 7,377.799 B2 5/2008 Diab et al. 7,377.799 B2 5/2008 Olab et al. 7,377.799 B2 5/2008 Olab et al. 7,377.799 B2 5/2008 Olab et al. 7,478.432 B2 9/2008 Al-Ali et al. 7,478.432 B2 1/2004 Diab et al. 7,478.702 B2 1/2008 Diab et al. 7,478.703 B2 1/2009 Dia							
6,721.585 B 4,2004 Parker 7,371,981 B2 5,2008 Abdull-Haffer 7,373,1981 B2 5,2008 Abdull-Haffer 7,373,1981 B2 5,2008 Abdull-Haffer 7,373,1981 B2 5,2008 Abdull-Haffer 7,373,1981 B2 5,2008 Abdull-Haffer 7,376,433 B1 5,2008 Abdull-Haffer 7,376,433 B1 5,2008 Abdull-Haffer 7,376,433 B1 5,2008 Abdull-Haffer 7,376,436 B1 5,2008 Abdull-Haffer 7,377,499 B2 5,2008 Al-Ali et al. 7,487,432 B2 9,2004 Al-Ali et al. 7,487,432 B2 9,2008 Al-Ali et al. 7,487,432 B2 9,2008 Al-Ali et al. 7,487,432 B2 9,2008 Al-Ali et al. 7,487,432 B2 1,2008 Biab et al. 8,826,419 B2 1,12004 Biab et al. 7,467,602 B2 1,22008 Biab et al. 6,830,781 B2 1,2004 Mills et al. 7,467,602 B2 1,22008 Biab et al. 6,830,788 B2 2,2005 Biab et al. 7,487,739 B2 1,22008 Biab et al. 6,830,788 B2 2,2005 Biab et al. 7,488,739 B2 1,22008 Biab et al. 6,830,788 B2 2,2005 Biab et al. 7,488,739 B2 1,22008 Biab et al. 6,830,438 B2 2,2005 Biab et al. 7,489,639 B2 2,2009 Biab et al. 6,830,438 B2 2,2005 Biab et al. 7,489,639 B2 2,2009 Biab et al. 6,830,438 B2 2,2005 Biab et al. 7,489,639 B3 2,2009 Biab et al. 6,931,438 B1 9,205 Al-Ali et al. 7,496,391 B2 2,2009 Biab et al. 6,931,438 B1 9,205 Al-Ali et al. 7,499,835 B2 2,2009 Biab et al. 6,931,438 B1 9,205 Al-Ali et al. 7,499,835 B2 2,2009 Biab et al. 6,931,438 B1 9,205 Al-Ali et al. 7,499,835 B2 2,2009 Biab et al. 6,931,438 B1 9,205 Al-Ali et al. 7,500,438 B2 2,2009 Biab et al. 7,500,438							
6,728,560 B2 42,004 Kolliae et al. 7,373,194 B2 5,2008 Weber et al. 6,745,660 B2 6,720,400 Parker 7,376,481 5,2008 Al-Ali et al. 7,377,394 B2 5,2008 Al-Ali et al. 7,377,394 B2 5,2008 Al-Ali et al. 7,377,396 B2 5,2008 Al-Ali et al. 7,377,399 B2 5,2008 Al-Ali et al. 7,377,399 B2 5,2008 Al-Ali et al. 7,478,379 B2 5,2008 Al-Ali et al. 7,478,379 B2 5,2008 Al-Ali et al. 7,478,478 B2 2,2008 Al-Ali et al. 7,478,478 B2 2,2008 Al-Ali et al. 7,478,478 B2 1,02008 Al-Ali et al. 7,478,478 B2 1,02008 Biab et al. 7,478,478 B2 1,02009 Bi				7,371,981	B2		
6,735,459 B2 5,2004 Parker 7,376,453 B1 5,2008 Diab et al. 7,375,445 B1 5,2008 Diab et al. 7,377,94 B2 5,2008 Weber et al. 6,760,607 B2 7,2004 Al-Ali 7,377,89 B2 5,2008 Weber et al. 6,770,607 B2 7,2004 Al-Ali 7,377,89 B2 5,2008 Weber et al. 6,770,209 B1 9,2004 Diab et al. 7,415,297 B2 8,2008 Al-Ali et al. 6,771,1994 B2 8,2004 Diab et al. 7,415,297 B2 8,2008 Al-Ali et al. 6,772,200 B1 9,2004 Diab et al. 7,428,432 B2 9,2008 Al-Ali et al. 6,813,511 B2 11,2004 Diab et al. 7,438,683 B2 10,2008 Al-Ali et al. 6,816,741 B2 11,2004 Diab et al. 7,440,787 B2 10,2008 Diab et al. 6,816,741 B2 11,2004 Diab et al. 7,440,787 B2 10,2008 Diab et al. 6,830,741 B2 11,2004 Diab et al. 7,467,002 B2 12,2008 Diab et al. 6,830,741 B2 11,2004 Diab et al. 7,467,002 B2 12,2008 Diab et al. 6,830,741 B2 12,2004 Milk et al. 7,467,002 B2 12,2008 Diab et al. 6,830,787 B2 2,2005 Parker 7,471,969 B2 12,2008 Diab et al. 6,830,787 B2 2,2005 Chali 7,483,729 B2 12,2008 Diab et al. 6,830,830,88 B2 2,2005 Al-Ali 7,483,729 B2 12,2008 Diab et al. 6,830,830,88 B2 2,2005 Al-Ali 7,483,730 B2 1,2009 Diab et al. 6,830,830,88 B2 2,2005 Al-Ali et al. 7,489,988 B2 2,2009 Diab et al. 6,830,43,730 B2 1,2008 Al-Ali et al. 7,469,331 B2 2,2009 Diab et al. 6,830,43,730 B2 2,2005 Al-Ali et al. 7,489,588 B2 2,2009 Diab et al. 6,930,345 B2 7,2005 Al-Ali et al. 7,499,341 B2 3,2009 Diab et al. 6,930,43,70 B2 8,2005 Kiani-Azarbayjany et al. 7,499,341 B2 3,2009 Diab et al. 6,930,43,70 B2 8,2005 Kiani-Azarbayjany et al. 7,590,494 B2 3,2009 Al-Ali et al. 6,930,436 B2 9,2005 Kiani-Azarbayjany et al. 7,590,494 B2 3,2009 Diab et al. 6,930,379 B2 9,2005 Al-Ali et al. 7,500,395 B2 3,2009 Diab et al. 7,640,833 B2 3,2009 Diab et al. 7,640,838 B2 3,2009 Diab et al. 7,640,838 B2 3,2009 Diab et							
6,745,060 B2 6,2004 Diab et al. 7,377,794 B2 5,2008 Al-Ali et al. 7,377,894 B2 5,2008 Weber et al. 6,770,028 B1 8,2004 Al-Ali 7,383,070 B2 6,2008 Diab et al. 7,378,990 B2 5,2008 Weber et al. 6,771,094 B2 8,2004 Al-Ali et al. 7,428,332 B2 9,2008 Al-Ali et al. 7,449,787 B2 10,2008 Diab et al. 7,449,787 B2 11,2004 Diab et al. 7,467,902 B2 12,2008 Weber et al. 6,830,711 B2 11,2004 Diab et al. 7,467,902 B2 12,2008 Diab et al. 6,830,711 B2 11,2004 Diab et al. 7,469,187 B2 12,2008 Diab et al. 6,830,711 B2 12,2008 Diab et al. 7,469,187 B2 12,2008 Diab et al. 6,830,781 B2 12,2005 Parker 7,471,969 B2 12,2008 Diab et al. 6,830,788 B2 2,2005 Parker 7,471,969 B2 12,2008 Diab et al. 6,830,788 B2 2,2005 Al-Ali et al. 7,483,729 B2 12,2009 Diab et al. 6,830,788 B2 2,2005 Al-Ali et al. 7,483,729 B2 12,2009 Diab et al. 6,830,482 B2 2,2005 Al-Ali et al. 7,489,339 B2 2,2009 Diab et al. 6,930,345 B2 7,2005 Al-Ali et al. 7,499,339 B2 2,2009 Diab et al. 6,931,268 B1 8,2005 Al-Ali et al. 7,499,339 B2 2,2009 Diab et al. 6,931,268 B1 8,2005 Kiani et al. 7,499,383 B2 2,009 Diab et al. 6,931,368 B2 12,000 Siani et al. 7,499,383 B2 2,009 Diab et al. 6,931,368 B2 12,000 Siani et al. 7,499,383 B2 2,009 Diab et al. 6,931,368 B2 12,000 Siani et al. 7,499,383 B2 2,009 Diab et al. 6,931,368 B2 12,000 Siani et al. 7,499,741 B2 3,009 Diab et al. 6,930,379 B2 12,000 Kiani et al. 7,499,741 B2 3,009 Diab et al. 6,930,379 B2 12,000 Kiani et al. 7,499,741 B2 3,009 Diab et al. 7,003,339 B2 12,000 Meber et al. 7,509,398 B2 2,000 Diab et al. 7,003,339 B2 12,000 Meber et al. 7,509,398 B2 2,000 Diab et al. 7,003,339 B2 12,000 Meber et al. 7,509,398 B2 2,000 Diab et al. 7,003,339 B2 12,000 Meber et al. 7,609,498 B2 2,000 Meber et al. 7,609,605 B2 2,000 Meber et al. 7,609,605 B2 2,000 Meber et al.							
6,760,607 Bl 8 7/2004 Ali et al. 7,377,899 Bz 5/2008 Weber et al. 7,378,7899 Bz 6,771,994 Bz 8/2004 Ali et al. 7,388,078 Bz 8/2004 Ali et al. 7,415,297 Bz 8/2008 Ali-Ali et al. 7,415,297 Bz 8/2008 Ali-Ali et al. 7,438,683 Bz 10/2008 Ali-Ali et al. 7,449,187 Bz 10/2008 Diab et al. 7,469,157 Bz 12/2008 Diab et al. 7,449,157 Bz 12/20				7,377,794	B2	5/2008	Al-Ali et al.
6.771,094 B2 82004 Kiani et al. 7.415,297 B2 82008 Al-Ali et al. 6.792,300 B1 9/2004 Diab et al. 7.428,683 B2 10/2008 Al-Ali et al. 6.813,511 B2 11/2004 Diab et al. 7.438,683 B2 10/2008 Al-Ali et al. 6.816,741 B2 11/2004 Diab et al. 7.449,863 B2 11/2008 Diab et al. 6.822,646 B2 11/2004 Al-Ali 1 7.445,240 B2 11/2008 Diab et al. 6.822,646 B2 11/2004 Mills et al. 7.467,030 B2 12,2008 Weber et al. 6.830,711 B2 12/2009 Mills et al. 7.467,157 B2 12/2008 Diab et al. 6.830,711 B2 12/2008 Weber et al. 7.471,911 B2 12/2008 Diab et al. 6.850,787 B2 2/2005 Weber et al. 7.471,911 B2 12/2008 Diab et al. 6.850,787 B2 2/2005 Weber et al. 7.471,911 B2 12/2008 Diab et al. 6.850,788 B2 2/2005 Caro et al. 7.471,911 B2 12/2008 Diab et al. 6.850,788 B2 2/2005 Caro et al. 7.488,730 B2 12/2009 Diab et al. 6.850,832,833 B2 2/2005 Al-Ali et al. 7.489,938 B2 2/2009 Diab et al. 6.898,452 B2 5/2005 Al-Ali et al. 7.490,339 B2 2/2009 Diab et al. 6.934,570 B2 8/2005 Kiani-Azarbayjany et al. 7.490,339 B2 2/2009 Diab et al. 6.934,570 B2 8/2005 Kiani-Azarbayjany et al. 7.490,339 B2 2/2009 Diab et al. 6.934,570 B2 8/2005 Kiani-Azarbayjany et al. 7.490,338 B2 3/2009 Diab et al. 6.934,348 B1 9/2005 Coffin, IV 7.500,950 B2 3/2009 Al-Ali et al. 6.951,588 B2 11/2005 Diab 6.951,588 B2 11/2005 Diab 6.951,588 B2 11/2005 Diab 6.951,588 B2 11/2005 Diab 7.520,328 B2 4/2009 Diab et al. 6.993,305 B2 1/2005 Diab 7.520,328 B2 4/2009 Diab et al. 6.993,313 B2 1/2006 Mason et al. 7.550,949 B2 5/2009 Al-Ali et al. 7.550,949 B2 5/2009 Diab et al. 6.993,313 B2 1/2006 Diab 7.520,838 B2 3/2009 Diab et al. 7.550,949 B2 5/2009 Diab et al. 7.550,949 B2 5/200	6,760,607 B2 7	7/2004	Al-Ali				
6,792,300 B1 9,2004 Diab et al. 7,428,432 B2 9,2008 Al. Ali et al. 6,813,511 B2 11/2004 Diab et al. 7,438,638 B2 10,2008 Al. Ali et al. 6,826,641 B2 11/2004 Diab Al. Ali 7,440,787 B2 11,2008 Diab et al. 7,450,7002 B2 11,2008 Diab et al. 7,450,7002 B2 11,2008 Diab et al. 7,450,7002 B2 12,2008 Diab et al. 7,450,7002 B2 12,2008 Diab et al. 6,830,711 B2 12,2005 Diab et al. 7,467,1002 B2 12,2008 Diab et al. 6,842,635 B1 1,2005 Parker 7,471,969 B2 12,2008 Diab et al. 6,850,787 B2 2,2005 Weber et al. 7,471,971 B2 12,2008 Diab et al. 6,850,788 B2 2,2005 Al. Ali T. 483,730 B2 1,2009 Al. Ali et al. 7,483,730 B2 1,2009 Al. Ali et al. 7,483,730 B2 1,2009 Diab et al. 6,861,639 B2 2,2005 Al. Ali et al. 7,496,391 B2 2,2009 Diab et al. 6,931,436 B2 7,2005 Al. Ali et al. 7,496,391 B2 2,2009 Diab et al. 6,931,436 B2 7,2005 Al. Ali et al. 7,496,391 B2 2,2009 Diab et al. 6,934,570 B2 8,2005 Kiani et al. 7,496,391 B2 2,2009 Diab et al. 6,934,570 B2 9,2005 Flaherty et al. 7,490,431 B2 3,2009 Al. Ali et al. 7,500,441 B2 3,2009 Al. Ali et al. 7,500,458 B2 2,2009 Al							
6.813.511 B2 11/2004 Diab et al. 7,438.683 B2 10/2008 Diab for al. 6.816.741 B2 11/2014 Diab for Al. Ali et al. 6.821.564 B2 11/2004 Diab for al. 7,434.240 B2 11/2008 Diab for al. 6.822.564 B2 11/2004 Diab et al. 7,457.002 B2 11/2008 Weber et al. 6.830.711 B2 11/2005 Parker 7,471.969 B2 11/2008 Diab et al. 6.830.713 B2 11/2005 Parker 7,471.969 B2 11/2008 Diab et al. 6.850.788 B2 1/2005 Weber et al. 7,471.971 B2 11/2008 Diab et al. 6.850.788 B2 1/2005 Weber et al. 7,471.971 B2 11/2009 Diab et al. 6.850.788 B2 1/2005 Al-Ali 7,483.729 B2 1/2009 Diab et al. 6.850.788 B2 1/2005 Al-Ali 7,483.730 B2 1/2009 Diab et al. 6.850.838 B2 1/2005 Carbon et al. 7,483.730 B2 1/2009 Diab et al. 6.850.838 B2 1/2005 Al-Ali et al. 7,496.391 B2 1/2009 Diab et al. 6.930.458 B2 1/2005 Al-Ali et al. 7,496.391 B2 1/2009 Diab et al. 6.930.458 B2 1/2005 Al-Ali et al. 7,496.391 B2 1/2009 Diab et al. 6.931.268 B1 1/2005 Al-Ali et al. 7,496.391 B2 1/2009 Diab et al. 6.934.579 B2 8/2005 Al-Ali et al. 7,496.391 B2 1/2009 Diab et al. 6.934.579 B2 8/2005 Kiani-dxarbayjany et al. 7,499.741 B2 3/2009 Diab et al. 6.934.378 B2 9/2005 Coffin. 10 1/2005 Diab 1/2005 Diab et al. 7,499.741 B2 3/2009 Diab et al. 6.934.878 B2 1/2005 Coffin. 10 1/2005 Diab 1	6.792.300 B1 9			7,428,432	B2	9/2008	Ali et al.
6,822,564 B2 11/2004 Al-Ali 7,454,240 B2 11/2008 Diab et al. 6,826,419 B2 11/2004 Mills et al. 7,469,157 B2 12/2008 Weber et al. 6,830,787 B2 2/2005 Weber et al. 7,471,979 B2 12/2008 Diab et al. 6,850,788 B2 2/2005 Weber et al. 7,471,971 B2 12/2008 Diab et al. 6,850,788 B2 2/2005 Weber et al. 7,471,971 B2 12/2008 Diab et al. 6,850,788 B2 2/2005 Caro et al. 7,471,971 B2 12/2008 Diab et al. 6,850,788 B2 2/2005 Caro et al. 7,483,729 B2 1/2009 Diab et al. 6,851,639 B2 2/2005 Caro et al. 7,483,730 B2 1/2009 Diab et al. 6,851,639 B2 2/2005 Caro et al. 7,496,391 B2 2/2009 Diab et al. 6,894,852 B2 5/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,496,393 B2 2/2009 Diab et al. 6,931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,496,393 B2 2/2009 Diab et al. 6,934,393 B2 2/2009 Al-Ali et al. 7,499,741 B2 3/2009 Al-Ali et al. 6,934,393 B2 3/2009 Al-Ali et al. 7,499,343 B2 3	6,813,511 B2 11	/2004	Diab et al.				
6,826,419 B2 11/2004 Diab et al. 7,467,002 B2 12/2008 Weber et al. 6,830,711 B2 12/2004 Diab et al. 7,467,107 B2 12/2008 Diab et al. 6,830,711 B2 12/2004 Diab et al. 7,471,969 B2 12/2008 Diab et al. 6,842,635 B1 1/2005 Parker 7,471,971 B2 12/2008 Diab et al. 6,850,787 B2 2/2005 Al-Ali 7,483,729 B2 1/2009 Al-Ali et al. 7,483,729 B2 1/2009 Al-Ali et al. 6,851,078 B2 2/2005 Al-Ali 7,483,730 B2 1/2009 Diab et al. 6,861,639 B2 3/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,861,639 B2 3/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,920,345 B2 7/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,931,570 B2 8/2005 Kiani-ta-zarbayjany et al. 7,496,391 B2 2/2009 Diab et al. 6,934,570 B2 8/2005 Kiani-ta-zarbayjany et al. 7,499,835 B2 3/2009 Diab et al. 6,934,570 B2 8/2005 Kiani-ta-zarbayjany et al. 7,499,835 B2 3/2009 Diab et al. 6,934,374 B1 9/2005 Coffin, IV 7,509,154 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Diab Al-Ali et al. 7,500,950 B2 3/2009 Diab et al. 6,961,598 B2 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,993,371 B2 1/2006 Mason et al. 7,530,949 B2 5/2009 Diab et al. 6,996,427 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 6,996,427 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 6,996,427 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 7,033,339 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 7,033,339 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 7,041,949 B2 5/2006 Mason et al. 7,530,949 B2 5/2009 Diab et al. 7,044,918 B2 5/2006 Mason et al. 7,647,983 B2 1/2009 Flaherty et al. 7,044,918 B2 5/2006 Diab et al. 7,647,983 B2 1/2000 Mills et al. 7,647,983 B2 1/2000 Mills et al. 7,644,918 B2 5/2006 Diab et al. 7,647,983 B2 1/2000 Mills et al. 7,647,983 B2 1/2000 Diab et al. 7,944,918 B2 5/2006 Diab et al. 7,944,948 B2 5/2006 Diab et al. 7,944,948 B	-,,						
6.830,711 B2 12/2004 Mills et al. 7,469,157 B2 12/2008 Diab et al. 6.850,787 B2 2/2005 Care et al. 7,471,971 B2 12/2008 Diab et al. 6.850,788 B2 2/2005 Care et al. 7,483,730 B2 1/2009 Diab et al. 6.850,788 B2 2/2005 Care et al. 7,483,730 B2 1/2009 Diab et al. 6.850,788 B2 2/2005 Care et al. 7,483,730 B2 1/2009 Diab et al. 6.851,838 B2 2/2005 Care et al. 7,483,730 B2 1/2009 Diab et al. 6.852,838 B2 2/2005 Al-Ali et al. 7,489,958 B2 2/2009 Diab et al. 6.934,570 B2 B2 7/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6.931,268 B1 8/2005 Kiani-Azarbayjany et al. 5,876,57 S 3/2009 Al-Ali et al. 5,931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,499,741 B2 3/2009 Diab et al. 6,931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,499,741 B2 3/2009 Diab et al. 6,931,303 B2 9/2005 Flaherty et al. 7,499,741 B2 3/2009 Diab et al. 6,933,305 B2 9/2005 Caffin, 1V 7,509,154 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Caffin, 1V 7,509,154 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Al-Ali 7,509,494 B2 3/2009 Al-Ali 6,961,598 B2 11/2005 Diab 7,510,849 B2 3/2009 Schurman et al. 6,979,812 B2 12/2005 Al-Ali 7,530,949 B2 3/2009 Diab et al. 6,979,812 B2 12/2005 Al-Ali 7,530,949 B2 3/2009 Diab et al. 6,993,371 B2 1/2006 Mason et al. 7,530,949 B2 5/2009 Diab et al. 6,993,371 B2 1/2006 Mason et al. 7,530,949 B2 5/2009 Al-Ali et al. 7,530,949 B2 5/2							
6.850,787 B2 2/2005 Weber et al. 7,471,971 B2 12/2008 Diab et al. 6.850,788 B2 2/2005 Al-Ali 7,483,779 B2 1/2009 Diab et al. 6.850,788 B2 2/2005 Caro et al. 7,483,730 B2 1/2009 Diab et al. 6.858,852 B2 5/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6.920,345 B2 7/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6.931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,499,374 B2 2/2009 Diab et al. 6.931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,499,335 B2 2/2009 Diab et al. 6.934,348 B1 9/2005 Kiani-Azarbayjany et al. 7,499,835 B2 2/2009 Diab et al. 6.943,486 B1 9/2005 Kiani et al. 7,499,835 B2 2/2009 Diab et al. 6.950,687 B2 9/2005 Al-Ali 7,500,950 B2 3/2009 Al-Ali et al. 6.950,687 B2 1/2005 Diab 7,510,849 B2 3/2009 Al-Al							
6,850,788 B2 2/2005 Al-Ali 7,483,729 B2 1/2009 Al-Ali et al. 6,852,083 B2 2/2005 Caro et al. 7,489,739 B2 2/2009 Diab et al. 6,861,639 B2 3/2005 Al-Ali 1 7,489,591 B2 2/2009 Diab et al. 6,920,345 B2 7/2005 Al-Ali et al. 7,496,393 B2 2/2009 Diab et al. 6,931,570 B2 8/2005 Kiani et al. 7,499,741 B2 3/2009 Al-Ali et al. 6,934,570 B2 8/2005 Kiani et al. 7,499,335 B2 3/2009 Al-Ali et al. 6,933,350 B2 9/2005 Flaherty et al. 7,500,950 B2 3/2009 Al-Ali et al. 6,943,348 B1 9/2005 Flaherty et al. 7,500,949 B2 3/2009 Al-Ali et al. 6,950,687 B2 1/2005 Diab 7,510,349 B2 3/2009 Al-Ali et al. 6,970,792 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
6,852,083 B2 2/2005 Caro et al. 7,489,758 B2 1/2009 Diab et al. 6,861,639 B2 3/2005 Al-Ali 7,489,958 B2 2/2009 Diab et al. 6,898,452 B2 5/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,920,345 B2 7/2005 Al-Ali et al. 7,496,393 B2 2/2009 Diab et al. 6,931,268 B1 8/2005 Kiani-Azarbayjany et al. D\$87,657 \$ 32,009 Al-Ali et al. 6,931,570 B2 8/2005 Kiani-Azarbayjany et al. 7,499,385 B2 3/2009 Diab et al. 6,934,570 B2 8/2005 Kiani-Azarbayjany et al. 7,499,385 B2 3/2009 Diab et al. 6,939,305 B2 9/2005 Flaherty et al. 7,509,154 B2 3/2009 Diab et al. 6,939,305 B2 9/2005 Coffin, IV 7,509,154 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Schurman et al. 6,970,792 B1 11/2005 Diab 7,526,328 B2 3/2009 Diab et al. 6,973,812 B2 1/2006 Kiani et al. 7,530,942 B1 5/2009 Diab et al. 6,993,371 B2 1/2006 Kiani et al. 7,530,949 B2 5/2009 Diab et al. 6,993,371 B2 1/2006 Kiani et al. 7,530,949 B2 5/2009 Diab et al. 6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 5/2009 Diab et al. 7,015,451 B2 3/2006 Diab et al. 7,563,110 B2 7/2009 Al-Ali et al. 7,014,161 B2 7/2006 Kiani et al. 7,5796,398 B2 5/2009 Diab et al. 7,014,161 B2 7/2006 Kiani et al. 7,618,375 B2 11/2009 Flaherty et al. 7,014,161 B2 7/2006 Malle et al. 7,647,088 B2 7/2009 Al-Ali et al. 7,014,161 B2 7/2006 Malle et al. 7,647,088 B2 7/2006 Malle et al. 7,647,088 B2 7/2006 Malle et al. 7,611,178 B2 7/2010 Al-Ali et al. 7,030,349 B2 7/2006 Mills et al. 7,611,178 B2 7/2010 Al-Ali et al. 7,041,060 B2 5/2006 Mills et al. 7,611,178 B2 7/2010 Al-Ali et al. 7,041,161 B2 7							
6,898,452 B2 5/2005 Al-Ali et al. 7,496,391 B2 2/2009 Diab et al. 6,920,345 B2 7/2005 Al-Ali et al. 7,496,393 B2 2/2009 Diab et al. 6,931,570 B2 8/2005 Kiani et al. 7,499,741 B2 3/2009 Al-Ali et al. 6,934,570 B2 8/2005 Kiani et al. 7,500,950 B2 3/2009 Al-Ali et al. 6,933,305 B2 9/2005 Flaherty et al. 7,500,950 B2 3/2009 Al-Ali et al. 6,950,687 B2 9/2005 Al-Ali 7,500,950 B2 3/2009 Al-Ali et al. 6,950,687 B2 9/2005 Al-Ali 7,509,494 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 1/2009 Diab et al. 6,979,812 B2 1/2006 Mason et al. 7,530,949 B2 5/2009 Diab 6,995,764 B2 1/2006 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
G.920,345 B2							
6,931,268 B1 8/2005 Kiani-Azarbayjany et al. 7,499,741 B2 3/2009 Diab et al. 6,939,305 B2 8/2005 Kiani et al. 7,499,835 B2 3/2009 Weber et al. 7,500,950 B2 3/2009 Al-Ali Ali et al. 7,500,949 B2 3/2009 Al-Ali et al. 7,510,949 B2 3/2009 Diab et al. 7,510,949 B2 3/2009 Diab et al. 7,510,949 B2 3/2009 Diab et al. 7,530,942 B1 5/2009 Diab et al. 7,530,942 B1 5/2009 Diab et al. 7,530,949 B2 5/2009 Al-Ali et al. 7,530,949 B2 7/2006 Al-Ali et al. 7,530,949 B2 7/2009 Al-Ali et al. 7,647,083 B2 1/2009 Al-Ali et al. 7,044,948 B2 7/2006 Al-Ali Ali Ali et al. 7,647,083 B2 1/2000 Al-Ali et al. 7,044,948 B2 5/2006 Al-Ali Ali Ali Ali Ali et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,948 B2 5/2006 Al-Ali Ali Ali Ali Ali Ali Ali Ali et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,948 B2 5/2006 Al-Ali Ali Ali Ali Ali Ali Ali et al. 7,761,128 B2 7/2010 Al-Ali et al. 7,044,948 B2 5/2006 Al-Ali Ali Ali Ali Ali Ali Ali Ali Ali Ali							
6,934,570 B2 8/2005 Kiani et al. 7,499,341 B2 3/2009 Weber et al. 6,934,348 B1 9/2005 Coffin, IV 7,500,950 B2 3/2009 Diab et al. 7,500,950 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 B1 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,979,812 B2 12/2005 Al-Ali 7,530,942 B1 5/2009 Diab et al. 6,993,371 B2 11/2006 Mason et al. 7,530,949 B2 5/2009 Diab et al. 6,993,371 B2 11/2006 Mason et al. 7,530,949 B2 5/2009 Diab et al. 6,996,427 B2 2/2006 Weber et al. 7,530,949 B2 5/2009 Diab et al. 7,503,338 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,030,338 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,030,338 B2 2/2006 Diab et al. 7,618,375 B2 11/2009 Flaherty et al. 7,041,451 B2 3/2006 Diab et al. 7,647,083 B2 1/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al-Ali D60,491 S 2/2010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali D60,491 S 2/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 5/2006 Diab Et al. 7,761,127 B2 7/2010 Parker 7,044,918 B2 5/2006 Diab Et al. 7,761,127 B2 7/2010 Parker 7,044,918 B2 5/2006 Diab T,764,982 B2 7/2010 Diab T,764,983 B2 6/2006 Mills et al. 7,044,918 B2 5/2006 Diab T,764,982 B2 7/2010 Diab T,764,983 B2 6/2006 Mills et al. 7,996,052 B2 8/2006 Mason et al. 7,996,054 B2 8/2006 Mason et al. 7,996,054 B2 8/2006 Mason et al. 7,894,313 B2 11/2010 Schurman et al. 7,142,901 B2 11/2006 Schur et al. 7,894,313 B2 11/2010 Schurman et al. 7,142,901 B2 11/2006 Schur et al. 7,894,313 B2 11/2010 Mason et al. 7,149,561 B2 11/2006 Schur et al. 7,894,313 B2 11/2010 Mason et al. 7,215,984 B2 5/2007 Diab et al. 7,894,315 B2 11/2010 Mason et al. 7,225,006 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Diab et al. 7,894,366 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Diab et al. 7,894,368 B2 2/2011 Al-Ali				D587,657	S		
6,939,305 B2 9/2005 Flaherty et al. 7,500,950 B2 3/2009 Al-Ali et al. 6,950,687 B2 9/2005 Al-Ali 7,509,154 B2 3/2009 Diab et al. 6,961,598 B2 11/2005 Diab 7,510,849 B2 3/2009 Schurman et al. 6,979,812 B2 12/2005 Al-Ali 7,530,942 B1 5/2009 Diab et al. 6,985,764 B2 1/2006 Mason et al. 7,530,942 B1 5/2009 Diab et al. 6,996,427 B2 2/2006 Alci et al. 7,530,945 B2 5/2009 Diab et al. 7,003,338 B2 2/2006 Weber et al. 7,530,945 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,536,398 B2 9/2009 Al-Ali et al. 7,003,339 B2 2/2006 Diab et al. 7,647,083 B2 9/2009 Al-Ali et al. 7,015,451 B2 3							
6,943,348 Bl 9/2005 Coffin, IV 7,509,154 B2 3/2009 Diab et al. 6,950,687 B2 9/2005 Diab 7,509,494 B2 3/2009 Schurman et al. 6,970,792 Bl 11/2005 Diab 7,510,849 B2 3/2009 Diab et al. 6,970,792 Bl 12/2005 Al-Ali 7,530,942 Bl 5/2009 Diab et al. 6,993,371 B2 1/2006 Kiani et al. 7,530,949 B2 5/2009 Diab et al. 6,993,371 B2 1/2006 Kiani et al. 7,530,949 B2 5/2009 Diab et al. 6,993,378 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,618,375 B2 11/2009 Flaherty et al. 7,015,451 B2 3/2006 Dalke et al. 5066,598 B2 11/2009 Flaherty et al. 7,027,849 B2 4/2006 Al et al. 564,008 B2 1/2010 Al-Ali et al. 7,037,49 B2 4/2006 Al-Ali RE41,317 E 5/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,128 B2 7/2010 Al-Ali et al. 7,096,052 B2 8/2006 Mills et al.							
6,961,598 B2 11/2005 Diab 7,510,849 B2 3/2009 Schurman et al. 6,970,792 B1 11/2005 Diab 7,526,328 B2 4/2009 Diab et al. 6,979,812 B2 12/2005 Al-Ali 7,530,949 B1 5/2009 Diab et al. 6,993,371 B2 1/2006 Mason et al. 7,530,945 B2 5/2009 Al Ali et al. 6,993,427 B2 2/2006 Ali et al. 7,530,945 B2 5/2009 Diab et al. 6,999,904 B2 2/2006 Ali et al. 7,553,110 B2 7/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,563,110 B2 7/2009 Al-Ali et al. 7,015,451 B2 3/2006 Dalke et al. D606,659 \$12/2009 Kiani et al. 7,027,849 B2 4/2006 Al et al. D609,193 \$2 22010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali RE41,317 E E/2010 Al-Ali et al. 7,044,918 B2 5/2006				7,509,154	B2		
6,970,792 B1 11/2005 Diab 7,526,328 B2 4/2009 Diab et al. 6,979,812 B2 12/2005 Al-Ali 7,530,942 B1 5/2009 Diab et al. 6,985,764 B2 1/2006 Kiani et al. 7,530,949 B2 5/2009 Al Ali et al. 6,996,427 B2 2/2006 Ali et al. 7,563,110 B2 7/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,663,310 B2 7/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,618,375 B2 11/2009 Flaherty et al. 7,015,451 B2 3/2006 Dalke et al. D606,659 8 1/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al et al. D614,305 8 4/2010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,041,060 B2 5/2006				7,509,494	B2		
6,985,764 B2 1/2006 Mason et al. 7,530,949 B2 5/2009 Al Ali et al. 6,993,371 B2 1/2006 Kiani et al. 7,530,955 B2 5/2009 Al-Ali et al. 6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,618,375 B2 11/2009 Flaherty et al. 7,015,451 B2 3/2006 Dalke et al. D606,659 S 12/2009 Kiani et al. 7,024,233 B2 4/2006 Al et al. D609,193 S 2/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,041,060 B2 5/2006 Al-Ali 7,761,128 B2 7/2010 Al-Ali et al. 7,096,052 B2 8/2006	- , ,						
6,993,371 B2 1/2006 Kiani et al. 7,530,955 B2 5/2009 Diab et al. 6,996,427 B2 2/2006 Ali et al. 7,563,110 B2 7/2009 Al-Ali et al. 6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,618,375 B2 11/2009 Flaherty et al. 7,015,451 B2 3/2006 Dalke et al. D609,193 S 2/2010 Al-Ali et al. 7,024,233 B2 4/2006 Al et al. D614,305 S 4/2010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 5/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,128 B2 7/2010 Al-Ali et al. 7,096,052 B2 8/20							
6,996,427 B2 2/2006 Ali et al. 7,563,110 B2 7/2009 Al-Ali et al. 6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Diab et al. 7,618,375 B2 11/2009 Flaherty et al. 7,003,339 B2 2/2006 Diab et al. D606,659 S 12/2009 Kiani et al. 7,015,451 B2 3/2006 Dalke et al. D609,193 S 2/2010 Al-Ali et al. 7,024,233 B2 4/2006 Al-Ali D614,305 S 4/2010 Al-Ali et al. 7,037,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,039,449 B2 5/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Mils et al. 7,761,128 B2 7/2010 Al-Ali et al. 7,067,893 B2 6/2006 Mils et al. 7,764,982 B2 7/2010 Dalke et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,132,641 B2 11/2006 Kiani et al. 7,822,452 B2 10/2010 Schurman et al. 7,149,561 B2 12/2006 Diab	, ,						
6,999,904 B2 2/2006 Weber et al. 7,596,398 B2 9/2009 Al-Ali et al. 7,003,338 B2 2/2006 Weber et al. 7,618,375 B2 11/2009 Flaherty et al. 7,003,339 B2 2/2006 Diab et al. D606,659 S 12/2009 Kiani et al. 7,015,451 B2 3/2006 Dalke et al. D609,193 S 2/2010 Al-Ali et al. 7,024,233 B2 4/2006 Al et al. D609,193 S 2/2010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 5/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab 7,761,128 B2 7/2010 Al-Ali et al. 7,096,052 B2 8/2006							
7,003,339 B2 2/2006 Diab et al. D606,659 S 12/2009 Kiani et al. 7,015,451 B2 3/2006 Dalke et al. 7,647,083 B2 1/2010 Al-Ali et al. 7,024,233 B2 4/2006 Al et al. D609,193 S 2/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al-Ali BE41,317 E 5/2010 Al-Ali et al. 7,030,749 B2 4/2006 Al-Ali T,729,733 B2 6/2010 Al-Ali et al. 7,030,749 B2 5/2006 Al-Ali T,729,733 B2 6/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. T,761,127 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab T,764,982 B2 7/2010 Al-Ali et al. 7,096,052 B2 8/2006 Mason et al. T,791,155 B2 9/2010 Diab 7,132,641 B2 11/2006				7,596,398	B2		
7,015,451 B2 3/2006 Dalke et al. 7,647,083 B2 1/2010 Al-Ali et al. 7,024,233 B2 4/2006 Al et al. D609,193 S 2/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,729,733 B2 6/2010 Al-Ali et al. 7,039,449 B2 5/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab 7,764,982 B2 7/2010 Al-Ali et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Diab et al. 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,822,5007 B2 5/2007 Al-Ali et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,024,233 B2 4/2006 Al et al. D609,193 S 2/2010 Al-Ali et al. 7,027,849 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali 7,030,749 B2 5/2006 Al-Ali 7,030,749 B2 5/2006 Al-Ali 7,041,060 B2 5/2006 Flaherty et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,041,060 B2 5/2006 Diab 7,761,128 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab 7,764,982 B2 7/2010 Dalke et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Kiani et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Kiani et al. 7,215,986 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,880,606 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,027,849 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali RE41,317 E 5/2010 Parker 7,030,749 B2 4/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,039,449 B2 5/2006 Flaherty et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab 7,764,128 B2 7/2010 Al-Ali et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,801,581 B2 9/2010 Diab 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Schurman et al. 7,142,901 B2 12/2006 Diab						2/2010	Al-Ali et al.
7,030,749 B2 4/2006 Al-Ali 7,729,733 B2 6/2010 Al-Ali et al. 7,039,449 B2 5/2006 Al-Ali 7,761,127 B2 7/2010 Al-Ali et al. 7,041,060 B2 5/2006 Flaherty et al. 7,761,128 B2 7/2010 Al-Ali et al. 7,044,918 B2 5/2006 Diab 7,764,982 B2 7/2010 Dalke et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,824,525 B2 10/2010 Diab 7,132,641 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,886,606 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Al-Ali et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,039,449 B2 5/2006 Al-Ali et al. 7,761,127 B2 7/2010 Al-Ali et al. 7,041,060 B2 5/2006 Diab 7,761,128 B2 7/2010 Dalke et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,215,986 B2 5/2007 Diab et al. 7,823,497 B2 1/2011 Weber et al. 7,225,006 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,894,868 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,044,918 B2 5/2006 Diab 7,764,982 B2 7/2010 Dalke et al. 7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Kiani et al. 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,225,006 B2 5/2007 Al-Ali et al. 7,880,666 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,894,868 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.				7,761,127	B2	7/2010	Al-Ali et al.
7,067,893 B2 6/2006 Mills et al. D621,516 S 8/2010 Kiani et al. 7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,855,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,225,006 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,096,052 B2 8/2006 Mason et al. 7,791,155 B2 9/2010 Diab 7,096,054 B2 8/2006 Abdul-Hafiz et al. 7,801,581 B2 9/2010 Diab 7,132,641 B2 11/2006 Schulz et al. 7,824,545 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al.		5/2006	Mills et al.				
7,132,641 B2 11/2006 Schulz et al. 7,822,452 B2 10/2010 Schurman et al. 7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.						9/2010	Diab
7,142,901 B2 11/2006 Kiani et al. RE41,912 E 11/2010 Parker 7,149,561 B2 12/2006 Diab 7,844,313 B2 11/2010 Kiani et al. 7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al. <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
7,186,966 B2 3/2007 Al-Ali 7,844,314 B2 11/2010 Al-Ali 7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,190,261 B2 3/2007 Al-Ali 7,844,315 B2 11/2010 Al-Ali 7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.	7,149,561 B2 12	2/2006	Diab	7,844,313	B2	11/2010	Kiani et al.
7,215,984 B2 5/2007 Diab et al. 7,865,222 B2 1/2011 Weber et al. 7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,215,986 B2 5/2007 Diab et al. 7,873,497 B2 1/2011 Weber et al. 7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali et al. 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,221,971 B2 5/2007 Diab et al. 7,880,606 B2 2/2011 Al-Ali 7,225,006 B2 5/2007 Al-Ali et al. 7,880,626 B2 2/2011 Al-Ali et al. 7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							
7,225,007 B2 5/2007 Al-Ali et al. 7,891,355 B2 2/2011 Al-Ali et al. RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.	7,221,971 B2 5	5/2007	Diab et al.	7,880,606	B2	2/2011	Al-Ali
RE39,672 E 6/2007 Shehada et al. 7,894,868 B2 2/2011 Al-Ali et al.							

(56)**References Cited** OTHER PUBLICATIONS U.S. PATENT DOCUMENTS Jan. 31, 2012 Office Action for Japanese Patent Application No. 2007-520308 filed on Jun. 6, 2005. 7,899,518 B2 3/2011 Trepagnier et al. Apr. 2, 2013 Office Action for Japanese Patent Application No. 7,904,132 B2 3/2011 Weber et al. 2007-520308 filed on Jun. 6, 2005. 7,909,772 B2 3/2011 Popov et al. Jul. 30, 2013 Decision of Refusal for Japanese Patent Application No. 7,910,875 B2 3/2011 Al-Ali 2007-520308 filed on Jun. 6, 2005. 8,423,106 B2 4/2013 Lamego et al. Jan. 28, 2011 Office Action for European Patent Application No. 05 2003/0163032 A1* 8/2003 Terry 600/322 756 364.5 filed on Jun. 6, 2005. 2004/0116788 A1 6/2004 Chernoguz et al. Jul. 12, 2012 Office Action for European Patent Application No. 05 2011/0237911 A1 9/2011 Lamego et al. 756 364.5 filed on Jun. 6, 2005. Oct. 10, 2006 International Search Report and Written Opinion for FOREIGN PATENT DOCUMENTS PCT Application No. PCT/US05/19757 filed on Jun. 6, 2005. Sep. 21, 2010 Supplemental Search Report for European Patent A 07-255709 Application No. 05 756 364.5 filed on Jun. 6, 2005. JР 10/1995 US 5,857,432, 01/1999, Thomas et al. (withdrawn) JР A 08-322822 12/1996 JР 10-507118 7/1998 JР 11-506652 6/1999

^{*} cited by examiner








FIG. 3







FIG. 34




F1G. 4





May 17, 2016







FIG. 8

May 17, 2016







FIG. 10






FIG. 12

MULTI-WAVELENGTH PHYSIOLOGICAL MONITOR

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 12/045,309, filed Mar. 10, 2008, which is a continuation of U.S. application Ser. No. 11/139,291, filed May 27, 2005, now U.S. Pat. No. 7,343,186, which claims priority from U.S. Provisional No. 60/586,069, filed Jul. 7, 2004, each of which is incorporated by reference herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the field of signal processing. More specifically, the present invention relates to the processing of measured signals which contain a primary signal portion and a secondary signal portion for the removal or derivation of either signal portion. The present invention is especially useful for physiological monitoring systems, including blood oxygen saturation measurement systems and oximeters.

2. Description of the Related Art

Blood oxygen saturation measurement systems, oximeters, and physiological monitors of the prior art generally utilize two different wavelengths of light to determine a patient's blood oxygen saturation level. In general, such systems provide two wavelengths of light to a target location on a patient's body. The systems then measure at least one signal indicative of the transmission or reflection of the two light wavelengths with respect to the tissue at the target location.

One such physiological monitor is taught by Diab et al. in U.S. Pat. No. 5,632,272, incorporated by reference in its ³⁵ entirety herein. One embodiment of Diab's physiological monitor provides light having a red wavelength and light having an infrared wavelength to one side of a patient's finger. A detector on the opposite side of the patient's finger measures the red and infrared wavelength light transmitted ⁴⁰ through the patient's finger and generates a measurement signal. A processor analyzes the measurement signal to determine red and infrared component signals. Possible saturation values are input to a saturation equation module which provides reference coefficients. The red or infrared component signal is processed with the reference coefficients to yield reference signal vectors.

The reference signal vectors and the red or infrared component signal are processed by a correlation canceller to generate output vectors. The output vectors are input into a master power curve module, which provides a blood oxygen saturation value for each possible saturation value input to the saturation equation module. The patient's blood oxygen saturation is determined based upon the power curve module output.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an arterial blood oxygen saturation curve in accordance with the prior art.

FIG. 2 illustrates an arterial blood oxygen saturation curve of a multi-wavelength physiological monitor in accordance with one embodiment of the present invention.

FIG. 3 is an example of a physiological monitor in accordance with one embodiment of the present invention.

FIG. 3A illustrates one embodiment of the low noise emitter current driver of the physiological monitor of FIG. 3.

2

FIG. 4 illustrates one embodiment of the front end analog signal conditioning circuitry and the analog to digital conversion circuitry of the physiological monitor of FIG. 3.

FIG. 5 illustrates one embodiment of the digital signal processing circuitry of FIG. 3.

FIG. 6 illustrates one embodiment of additional operations performed by the digital signal processing circuitry of FIG. 3.

FIG. 7 illustrates one embodiment of the demodulation module of FIG. 6.

FIG. 8 illustrates one embodiment of the sub-sampling module of FIG. 6.

FIG. 9 illustrates one embodiment of the statistics module of FIG. 6.

FIG. 10 illustrates a block diagram of the operations of one embodiment of the saturation transform module of FIG. 6.

FIG. 11 illustrates a saturation transform curve in accordance with one embodiment of the present invention.

FIG. 12 illustrates a block diagram of the operation of one 20 embodiment of the saturation calculation module of FIG. 6.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

A multi-wavelength physiological monitor in accordance with one embodiment of the present invention determines blood oxygen saturation by propagating multi-wavelength energy through a medium, such as a portion of a patient's body where blood flows close to the body surface. For example, in one embodiment, energy is propagated through an ear lobe, a digit (such as a finger or toe), a forehead, or a scalp (such as a fetus's scalp). An attenuated signal is measured after energy propagation through, or reflection from the medium. The physiological monitor determines the saturation of oxygenated blood in the patient based at least in part upon the measured signal.

It is well known by those of skill in the art that freshly oxygenated blood is pumped at high pressure from the heart into the arteries for use by the body. The volume of blood in the arteries varies with the heartbeat. This variation gives rise to a variation in energy absorption at the heartbeat rate, or the pulse.

Oxygen depleted, or deoxygenated, blood is returned to the heart through the veins with unused oxygenated blood. Unlike the arteries, the volume of blood in the veins varies with the rate of breathing, which is typically much slower than the heartbeat. Since the blood pressure in the veins is typically much lower than that of the arteries, the volume of blood in the veins varies in response to motion, such as a patient raising or lowering her arm. Changes in blood volume within the veins cause changes in vein thicknesses. Therefore, when there is no motion induced variation in the thickness of the veins, venous blood causes a low frequency variation in energy absorption, which is related to the rate of breathing. However, when erratic, motion-induced variations in the thickness of the veins occur, the low frequency variation in absorption is coupled with an erratic variation in energy absorption due to the erratic motion.

In one embodiment, absorption measurements are based upon the transmission of energy through a medium. In one embodiment, multiple light emitting diodes (LEDs) are positioned on one side of a portion of the body where blood flows close to the body's surface, such as a finger, and a photodetector is positioned on the opposite side of the surface. In another embodiment one or more such LEDs emit light of different wavelengths. In one embodiment, one LED emits a visible wavelength, such as red, and the other LED emits an

infrared wavelength. However, one skilled in the art will realize that other wavelength combinations could be used.

The finger comprises skin, tissue, muscle, both arterial blood and venous blood, fat, etc., each of which absorbs light energy differently due to different absorption coefficients, different concentrations, different thicknesses, and changing optical pathlengths. When the patient is not moving, absorption is substantially constant except for variations due to the flow of blood through the skin, tissue, muscle, etc. A constant attenuation can be determined and subtracted from the measured signal via traditional filtering techniques. However, when the patient moves, perturbations such as changing optical pathlengths occur. Such perturbations may be due to movement of background fluids, (such as venous blood, which has a different saturation than arterial blood). There- 15 fore, the measured signal becomes erratic. Erratic, motioninduced noise typically cannot be predetermined and subtracted from the measured signal via traditional filtering techniques. Thus, determining the oxygen saturation of arterial blood and venous in erratic, motion-induced noise envi- 20 ronments, blood becomes more difficult.

In one embodiment, a physiological monitor measures light transmission through a patient's finger to determine arterial blood oxygen saturation. In some cases, however, the measured light signal contains noise, or other secondary signal, due to an event, such as patient movement during signal measurement. In such case, the signal measured by the physiological monitor includes a primary portion, related to the blood oxygen saturation of the patient, and a secondary portion, related to the noisy, erratic, motion-induced secondary signal. The physiological monitor processes the measured signal to determine the patient's blood oxygen saturation based upon the signal's primary portion.

In one embodiment, the physiological monitor utilizes a processor to determine a secondary reference signal n'(t) or N_{ref} . The secondary reference signal n'(t) is used to determine the primary portion of the measured signal. In one embodiment, the secondary reference signal n'(t) is input to a multivariate process estimator, which removes the erratic, motion-induced secondary signal portions from the measured signal. 40 In another embodiment, the processor determines a primary signal reference signal s'(t) which is used for display purposes or for input to a multi-variate process estimator to derive information about patient movement and venous blood oxygen saturation.

FIG. 1 illustrates an arterial blood oxygen saturation curve 100 representative of the sensitivity of blood oxygen saturation systems of the prior art. Such systems utilize two different wavelengths of light (such as red and infrared wavelength light) to determine blood oxygen saturation. Arterial blood oxygen saturation (SaO $_2$) is represented on the y-axis of the curve 100. The x-axis represents ratios of a red wavelength light transmission signal and an infrared wavelength light transmission signal.

An ideal saturation curve 102 would be highly accurate at 55 all values. However, due to the limitations of using only two wavelengths of light, such systems typically operate between a lower range curve 104 and an upper range curve 106. Such blood oxygen saturation systems typically exhibit highly accurate, low tolerance 107 measurements at high saturation ovalues 108, but at lower saturation values 110, that accuracy decreases, and increased tolerance 111 results.

The arterial blood oxygen saturation curve **120** of a multi-wavelength physiological monitor in accordance with one embodiment of the present invention is shown in FIG. **2**. The multi-wavelength system utilizes at least three different wavelengths of light $(\lambda_1, \lambda_2, \ldots, \lambda_n)$ to determine blood

4

oxygen saturation. Arterial blood oxygen saturation (SaO₂) is represented on the y-axis of the curve **120**. The x-axis represents ratios of composite signals, each comprising signals based upon the light transmission of the various light wavelengths $(\lambda_1, \lambda_2, \ldots, \lambda_n)$. Each ratio r can be express by:

$$r = \frac{\sum_{i=1}^{n} \alpha_{i} N P_{RMS,i}}{\sum_{i=1}^{n} \beta_{i} N P_{RMS,i}}$$

where n is the number of wavelengths of light utilized by the multi-wavelength physiological monitor, NP_{RMS,i} is the normalized plethysmographic waveform of the ith wavelength light source, and α_i and β_i are vector coefficients of known constants that are determined based upon fitting and/or calibration using experimental data and/or model(s).

The curve 120 contains lower and upper limit range curves 122, 124. However, the lower and upper limit range curves 122, 124 of the multi-wavelength physiological monitor are more linear than the lower and upper range curves 104, 106 of the dual-wavelength blood oximeter described above, as illustrated in FIG. 1. In addition, the lower and upper limit range curves 122, 124 of the multi-wavelength physiological monitor exhibit higher accuracy and lower tolerance 126 than the dual-wavelength blood oximeter of FIG. 1, particularly at lower arterial blood oxygen saturation levels. In certain cases, such as during the monitoring of neonates, or persons with low blood-oxygen saturation, it is desirable for the physiological monitor to exhibit increased accuracy at lower saturation levels. For example, when providing oxygen to a neonate, it is often critical that neither too much oxygen nor too little oxygen is provided.

A schematic of one embodiment of a multi-wavelength physiological monitor for pulse oximetry is shown in FIGS. 3-5. FIG. 3 depicts a general hardware block diagram of a multi-wavelength pulse oximeter 299. A sensor 300 has n LEDs 302, which in one embodiment are at least three light emitters. The n LEDs 302 emit light of different wavelengths $(\lambda_1, \lambda_2, \dots \lambda_n)$. In one embodiment, the n LEDs **302** include four, six, eight or sixteen LEDs of different wavelengths. In one embodiment, the n LEDs 302 are placed adjacent a finger 310. A photodetector 320 receives light from the n LEDs 302 after it has been attenuated by passing through the finger. The photodetector 320 produces at least one electrical signal corresponding to the received, attenuated light. In one embodiment, the photodetector 320 is located opposite the n LEDs 302 on the opposite side of the finger 310. The photodetector 320 is connected to front end analog signal conditioning circuitry 330.

The front end analog signal conditioning circuitry 330 has outputs that are coupled to an analog to digital conversion circuit 332. The analog to digital conversion circuit 332 has outputs that are coupled to a digital signal processing system 334. The digital signal processing system 334 provides desired parameters as outputs for a display 336. Outputs for the display 336 include, for example, blood oxygen saturation, heart rate, and a clean plethysmographic waveform.

The signal processing system also provides an emitter current control output 337 to a digital-to-analog converter circuit 338. The digital-to-analog converter circuit 338 provides control information to emitter current drivers 340. The emitter drivers 340 are coupled to the n light emitters 302. The digital

signal processing system 334 also provides a gain control output 343 for front end analog signal conditioning circuitry 330

FIG. 3A illustrates one embodiment of the drivers 340 and the digital to analog conversion circuit 338. As depicted in 5 FIG. 3A, the digital-to-analog conversion circuit 338 includes first and second input latches 321, 322, a synchronizing latch 323, a voltage reference 324, and a digital to analog conversion circuit 325. The emitter current drivers 340 include first and second switch banks 326, 327, and n voltage to current 10 converters 328. LED emitters 302 of FIG. 3 are coupled to the output of the emitter current drives 340.

The driver depicted in FIG. 3A is advantageous in that the present inventors recognized that much of the noise in the oximeter 299 of FIG. 3 is caused by the LED emitters 302. 15 Therefore, the emitter driver circuit of FIG. 3A is designed to minimize the noise from the emitters 302. The first and second input latches 321, 322 are connected directly to the DSP bus. Therefore, these latches significantly minimizes the bandwidth (resulting in noise) present on the DSP bus which 20 passes through to the driver circuitry of FIG. 3A. The output of the first and second input latches only changes when these latched detect their address on the DSP bus. The first input latch 321 receives the setting for the digital to analog converter circuit 325. The second input latch 322 receives switch- 25 ing control data for the switch banks 326, 327. The synchronizing latch 323 accepts the synchronizing pulses which maintain synchronization between the activation of emitters 302 and the analog to digital conversion circuit 332

The voltage reference is chosen as a low noise DC voltage 30 reference for the digital to analog conversion circuit **325**. In addition, in the present embodiment, the voltage reference has a lowpass output filter with a very low corner frequency (e.g., 1 Hz in the present embodiment). The digital to analog converter **325** also has a lowpass filter at its output with a very low corner frequency (e.g., 1 Hz). The digital to analog converter provides signals used to drive each of the emitters **302**.

In the present embodiment, the output of the voltage to current converters 328 are switched such that, only one emitter is active at any given time. In addition, the voltage to 40 current converter for the inactive emitter is switched off at its input as well, such that it is deactivated. This reduces noise from the switching and voltage to current conversion circuitry. In the present embodiment, low noise voltage to current converters 328 are selected (e.g., Op 27 Op Amps), and 45 the feedback loop is configured to have a low pass filter to reduce noise. In the present embodiment, the low pass filtering function of the voltage to current converters 328 has a corner frequency of just above 625 Hz, which is the switching speed for the emitters 302, as further discussed below. 50 Accordingly, the driver circuit embodiment of FIG. 3A, minimizes the noise of the emitters 302.

In general, the n light emitters 302 each emit light energy of a different wavelength, which is absorbed by the finger 310 and received by the photodetector 320. The photodetector 320 55 produces an electrical signal which corresponds to the intensity of the light energy striking the photodetector 320. The front end analog signal conditioning circuitry 330 receives the intensity signals and filters and conditions these signals as further described below for further processing. The resultant signals are provided to the analog-to-digital conversion circuitry 332, which converts the analog signals to digital signals for further processing by the digital signal processing system 334. The digital signal processing system 334 utilizes the signals in order to provide a what will be called herein a 65 "saturation transform." It should be understood, that for parameters other than blood saturation monitoring, the satu-

6

ration transform could be referred to as a concentration transform, in-vivo transform, or the like, depending on the desired parameter. The term "saturation transform" is used to describe an operation which converts the sample data from time domain to saturation domain values, as will be apparent from the discussion below. In the present embodiment, the output of the digital signal processing system 334 provides clean plethysmographic waveforms of the detected signals and provides values for oxygen saturation and pulse rate to the display 336.

It should be understood that in different embodiments of the present invention, one or more of the outputs may be provided. The digital signal processing system 334 also provides control for driving the n light emitters 302 with an emitter current control signal on the emitter current control output 337. This value is a digital value which is converted by the digital-to-analog conversion circuit 338, which provides a control signal to the emitter current drivers 340. The emitter current drivers 340 provide the appropriate current drive for the n light emitters 302. Further detail of the operation of the multi-wavelength physiological monitor for pulse oximetry is explained below.

In the present embodiment, the n light emitters 302 are driven via the emitter current driver 340 to provide light transmission with digital modulation at 625 Hz. In the present embodiment, the n light emitters 302 are driven at a power level that provides an acceptable intensity for detection by the detector 320 and for conditioning by the front end analog signal conditioning circuitry 330. Once this energy level is determined for a given patient by the digital signal processing system 334, the current level for the n light emitters 302 is maintained substantially constant. It should be understood, however, that the current could be adjusted for changes in the ambient room light and other changes that would affect the voltage input to the front end analog signal conditioning circuitry 330.

In one embodiment, the n light emitters 302 are modulated as follows: for one complete 625 Hz cycle, each emitter 302 is activated for one ½n cycle, and off for the remaining (2n-1)/2n cycle. In order to only receive one signal at a time 302, the emitters are cycled on and off alternatively, in sequence, with each only active for a ½n cycle per 625 Hz cycle, with a ½n cycle separating the active times. The light signal is attenuated (e.g., amplitude modulated) by the pumping of blood through the finger 310 (or other sample medium). The attenuated (e.g., amplitude modulated) signal is detected by the photodetector 320 at the 625 Hz carrier frequency for the multi-wavelength light. Because only a single photodetector 320 is used, the photodetector 320 receives all light wavelength signals to form a composite time division signal.

The composite time division signal is provided to the front analog signal conditioning circuitry 330. Additional detail regarding the front end analog signal conditioning circuitry 330 and the analog to digital converter circuit 332 is illustrated in FIG. 4. As depicted in FIG. 4, in one embodiment, the front end circuitry 330 has a preamplifier 342, a high pass filter 344, an amplifier 346, a programmable gain amplifier 348, and a low pass filter 350. In one embodiment, the preamplifier 342 is a transimpedance amplifier that converts the composite current signal from the photodetector 320 to a corresponding voltage signal, and amplifies the signal. In the present embodiment, the preamplifier has a predetermined gain to boost the signal amplitude for ease of processing. In the present embodiment, the source voltages for the preamplifier 342 are -15 VDC and +15 VDC. As will be understood, the attenuated signal contains a component representing ambient light as well as a component representing the each of

the multi-wavelengths of light over time. If there is light in the vicinity of the sensor 300 other than the multi-wavelengths of light from the n light emitters 302, this ambient light is detected by the photodetector 320. Accordingly, the gain of the preamplifier is selected in order to prevent the ambient bight in the signal from saturating the preamplifier under normal and reasonable operating conditions.

In one embodiment, the preamplifier 342 includes an Analog Devices AD743JR OpAmp. This transimpedance amplifier is particularly advantageous in that it exhibits several desired features for the system described, such as: low equivalent input voltage noise, low equivalent input current noise, low input bias current, high gain bandwidth product, low total harmonic distortion, high common mode rejection, high open loop gain, and a high power supply rejection ratio.

The output of the preamplifier 342 is coupled to an input of the high pass filter 344. The output of the preamplifier also provides a first input 346 to the analog to digital conversion circuit 332. In the present embodiment, the high pass filter is 20 a single-pole filter with a corner frequency of about ½-1 Hz. However, the corner frequency is readily raised to about 90 Hz in one embodiment. As will be understood, the 625 Hz carrier frequency of the multi-wavelength light signal is well above a 90 Hz corner frequency. The high-pass filter 344 has 25 an output coupled as an input to an amplifier 346. In the present embodiment, the amplifier 346 comprises a unity gain amplifier. However, the gain of the amplifier 346 is adjustable by the variation of a single resistor. The gain of the amplifier 342 is 30 decreased to compensate for the effects of ambient light.

The output of the amplifier 346 provides an input to a programmable gain amplifier 348. The programmable gain amplifier 348 also accepts a programming input from the digital signal processing system 334 on a gain control signal 35 line 343. In one embodiment, the gain of the programmable gain amplifier 348 is digitally programmable. The gain is adjusted dynamically at initialization or at sensor placement due to changes in the medium (e.g., the finger) and due to variations in the medium from patient to patient. Therefore, a 40 dynamically adjustable amplifier is provided by the programmable gain amplifier 348 in order to obtain a signal suitable for processing.

The programmable gain amplifier 348 is also advantageous in an alternative embodiment in which the emitter drive cur- 45 rent is held constant. In the present embodiment, the emitter drive current is adjusted for each patient in order to obtain the proper dynamic range at the input of the analog to digital conversion circuit 332. However, changing the emitter drive current can alter the emitter wavelength, which in turn affects 50 the end result in oximetry calculations. Accordingly, in another embodiment, it is advantageous to fix the emitter drive current for all patients. In an alternative embodiment of the present invention, the programmable gain amplifier can be adjusted by the DSP in order to obtain a signal at the input to 55 the analog to digital conversion circuit which is properly within the dynamic range (+3 V to -3 V in the present embodiment) of the analog to digital conversion circuit 332. In this manner, the emitter drive current could be fixed for all patients, eliminating wavelength shift due to emitter current 60 drive changes.

The output of the programmable gain amplifier 348 couples as an input to a low-pass filter 350. Advantageously, the low pass filter 350 is a single-pole filter with a corner frequency of approximately 10 kHz in the present embodiment. This low pass filter provides anti-aliasing in the present embodiment.

8

The output of the low-pass filter 350 provides a second input 352 to the analog-to-digital conversion circuit 332. In the present embodiment, the analog-to-digital converter 354 and a second analog-to-digital converter 356. Advantageously, the first analog-to-digital converter 354 accepts input from the first input 346 to the analog-to-digital converter 356 accepts input on the second analog to digital converter 356 accepts input on the second input 352 to the analog-to-digital conversion circuitry 332.

In one embodiment, the first analog-to-digital converter 354 is a diagnostic analog-to-digital converter. The diagnostic task (performed by the digital signal processing system) is to read the output of the detector as amplified by the preamplifier 342 in order to determine if the signal is saturating the input to the high-pass filter 344. In the present embodiment, if the input to the high pass filter 344 becomes saturated, the front end analog signal conditioning circuits 330 provides a "0" output. Alternatively, in another embodiment, a first analog-to-digital converter 354 is not used.

The second analog-to-digital converter 356 accepts the conditioned composite analog signal from the front end signal conditioning circuitry 330 and converts the signal to digital form. In the present embodiment, the second analog to digital converter 356 comprises a single-channel, delta-sigma converter. In the present embodiment, a Crystal Semiconductor CS5317-KS delta-sigma analog to digital converter is used. Such a converter is advantageous in that it is low cost and exhibits low noise characteristics. More specifically, a delta-sigma converter consists of two major portions: a noise modulator and a decimation filter. The selected converter uses a second order analog delta-sigma modulator to provide noise shaping. Noise shaping refers to changing the noise spectrum from a flat response to a response where noise at the lower frequencies has been reduced by increasing noise at higher frequencies. The decimation filter then cuts out the reshaped, higher frequency noise to provide 16-bit performance at a lower frequency. The present converter samples the data 128 times for every 16 bit data word that it produces. In this manner, the converter provides excellent noise rejection, dynamic range and low harmonic distortion, that help in critical measurement situations like low perfusion and electrocautery.

In addition, by using a single-channel converter, there is no need to tune two or more channels to each other. The delta-sigma converter is also advantageous in that it exhibits noise shaping, for improved noise control. An exemplary analog to digital converter is a Crystal Semiconductor CS5317. In the present embodiment, the second analog to digital converter 356 samples the signal at a 20 kHz sample rate. The output of the second analog to digital converter 356 provides data samples at 20 kHz to the digital signal processing system 334 (FIG. 3)

The digital signal processing system 334 is illustrated in additional detail in FIG. 5. In the present embodiment, the digital signal processing system includes a microcontroller 360, a digital signal processor (DSP) 362, a program memory 364, a sample buffer 366, a data memory 368, a read only memory 370 and communication registers 372. In one embodiment, the digital signal processor 362 is an Analog Devices AD 21020, although other digital signal processors may be employed, as is well known by those of skill in the art. In one embodiment, the microcontroller 360 comprises a Motorola 68HC05, with built in program memory. In the present embodiment, the sample buffer 366 is a buffer which accepts the 20 kHz sample data from the analog to digital conversion circuit 332 for storage in the data memory 368. In

the present embodiment, the data memory 368 comprises 32 kWords (words being 40 bits in the present embodiment) of static random access memory. Other chips, data rates and data memory configurations may be employed, as is well known to those of skill in the art.

In one embodiment, the microcontroller 360 is coupled to the DSP 362 via a conventional JTAG Tap line. The microcontroller 360 transmits the boot loader for the DSP 362 to the program memory 364 via the Tap line, and then allows the DSP 362 to boot from the program memory 364. The boot loader in program memory 364 then causes the transfer of the operating instructions for the DSP 362 from the read only memory 370 to the program memory 364. Advantageously, the program memory 364 is a very high speed memory for the DSP 362. The microcontroller 360 provides the emitter current control and gain control signals via the communications register 372.

FIGS. 6-10 depict functional block diagrams of the operations of the multi-wavelength pulse oximeter 299 that in one 20 embodiment are executed by the digital signal processing system 334. The signal processing functions described below are carried out by the DSP 362 in the present embodiment, with the microcontroller 360 providing system management. In the present embodiment, the operation is software/firm- 25 ware controlled. FIG. 6 depicts a generalized functional block diagram for the operations performed on the 20 kHz sample data entering the digital signal processing system 334. As illustrated in FIG. 6, a demodulation operation, as represented in a demodulation module **400**, is first performed. Sub-sampling, as represented by sub-sampling operation 402, is then performed on the resulting data. Certain statistics are calculated, as represented in a statistics module 404. A saturation transform is performed, as represented in a saturation transform module 406, on the data resulting from the sub-sampling 35 operation 402. The data subjected to the statistics operations and the data subjected to the saturation transform operations are forwarded to saturation operations, as represented by a saturation calculation module 408 and pulse rate operations, as represented by pulse rate calculation module 410.

In general, the demodulation operation separates each of the multi-wavelength signals from the composite signal and removes the carrier frequency, leaving raw data points. The raw data points are provided at intervals (e.g., at 625 Hz) to the sub-sampling operation 402, which in one embodiment, 45 reduces the samples by an order of 10 from samples at 625 Hz to samples at 62.5 Hz. The sub-sampling operation also provides some filtering on the samples. The resulting data is subjected to statistics and saturation transform operations **404**, **406** to calculate a saturation value, which is very tolerant 50 to motion artifacts and other noise in the signal. The saturation value is ascertained in the saturation calculation module 408, and a pulse rate and a clean plethysmographic waveform are obtained through the pulse rate module 410. Additional details regarding the various operations are provided in connection with FIGS. 7-10.

FIG. 7 illustrates one embodiment of the operation of the demodulation module 400. One embodiment of a composite, modulated signal format is depicted in FIG. 7. One full 625 Hz cycle of the n-wavelength, composite signal is depicted in 60 FIG. 7 with the first $\frac{1}{2}$ n cycle including the first light wavelength signal plus ambient light signal, the second $\frac{1}{2}$ n cycle including the second light wavelength signal plus ambient light signal plus ambient light signal, and the fourth $\frac{1}{2}$ n cycle including an ambient light signal. In one embodiment, this pattern repeats n times, wherein the $(2n-1)^{th}$ $\frac{1}{2}$ n cycle includes the n^{th} light wave-

10

length signal plus an ambient light signal, and the 2nth cycle includes an ambient light signal.

Alternatively, in another embodiment, the first cycle of the composite signal includes the first light wavelength signal plus an ambient light signal, and the second cycle of the composite signal includes the second light wavelength signal plus an ambient light signal. This pattern repeats to the nth cycle of the composite signal, which includes the nth wavelength signal plus an ambient light signal. In such embodiment, the (n+1)th cycle includes only an ambient light signal.

As depicted in FIG. 7, when a 20 kHz sampling frequency is utilized, the single full cycle at 625 Hz described above comprises 32 samples of 20 kHz data, eight samples relating to the first wavelength of light plus ambient light, eight samples relating to ambient light, eight samples relating to the second wavelength of light plus ambient light, finally eight samples related to ambient light, etc. This pattern repeats for each of the n wavelength of light.

Because the signal processing system 334 controls the activation of the light emitters 302, the entire system is synchronous. In one embodiment, the data is synchronously divided (and thereby demodulated) into 2n 8-sample packets, with a time division demultiplexing operation as represented in a demultiplexing module 421. One eight-sample packet 422 represents the first wavelength of light plus ambient light signal, a second eight-sample packet 424 represents an ambient light signal, a third eight-sample packet (not shown) represents the attenuated second wavelength of light plus ambient light signal, a fourth eight-sample packet (not shown) represents the ambient light signal. This structure repeats until the $(2n-1)^{th}$ eight-sample packet **426**, which represents the attenuated nth wavelength of light plus ambient light signal, and 2nth eight-sample packet 428, which represents an ambient light signal. A select signal synchronously controls the demultiplexing operation so as to divide the time-division multiplexed composite signal at the input of the demultiplexer 421 into its n subparts.

In one embodiment, the last several samples from each packet are then processed as follows. A sum of the last four samples from each packet is calculated, as represented in the summing operations 430 of FIG. 7. In the present embodiment, the last four samples are used because a low pass filter in the analog to digital converter 356 of the present embodiment has a settling time. However, any number of samples may be so summed. The selection of the number of samples to be summed will be determined based at least in part on the settling time of the n LEDs 302 (not shown). Collecting the last four samples from each 8-sample packet allows the previous signal to clear. This summing operation provides an integration operation which enhances noise immunity. The sum of the respective ambient light samples is then subtracted from the sum of each of the individual wavelength samples, as represented in the subtraction modules 438. It should be understood that in one embodiment, for n wavelengths of light, there will be a subtraction modules 438. The subtraction operation provides some attenuation of the ambient light signal present in the data. In the present embodiment, it has been found that approximately 20 dB attenuation of the ambient light is provided by the operations of the subtraction modules 438. The resultant individual wavelength sum values are divided by the number of samples summed in summing operations 430. In the present embodiment, the sum values are divided by four, as represented in the divide modules 442. Each resultant value provides one sample each of each of the individual wavelengths light signals at 625 Hz.

It should be understood that the carrier frequency has been removed by the demodulation operation 400. In one embodi-

ment, the 625 Hz sample data at the output of the demodulation operation 400 is sample data without the carrier frequency. In order to satisfy Nyquist sampling requirements, less than 20 Hz is used (understanding that the human pulse is about 25 to 250 beats per minute, or about 0.4 Hz-4 Hz). 5 Accordingly, the 625 Hz resolution is reduced to 62.5 Hz in the sub-sampling operation 402 (not shown). Although in the present embodiment the sub-sampling operation 400 effectively reduces the data rate by 10:1, other such sub-sampling ratios may be used. The term "sub-sampling," in addition to 10 its ordinary meaning, is intended to include decimation and sub-sampling at any appropriate rate or ratio. Such methods are well known to those of skill in the art.

FIG. 8 illustrates the operations of one embodiment of the sub-sampling module 402 of FIG. 6. The multi-wavelength 15 light sample data is provided at 625 Hz to corresponding buffers or filters 450. It should be understood that in one embodiment, for n wavelengths of light, there are n corresponding buffers or filters 450. In the present embodiment, the multi-wavelength light buffers/filters **450** are 519 samples 20 deep, although other such buffers or filters may be used, as is well known to those of skill in the art. In one embodiment, the buffer filters 450 function as continuous first-in, first-out buffers (FIFO buffers). The 519 samples of each buffer filter 450 are subjected to low-pass filtering. Preferably, the low-pass 25 filtering has a cutoff frequency of approximately 7.5 Hz with attenuation of approximately -110 dB. The buffer/filters 450 form a Finite Impulse Response (FIR) filter with coefficients for 519 taps. In order to reduce the sample frequency by ten, the low-pass filter calculation is performed every ten samples, 30 as represented in sub-sample modules 454. In other words, with the transfer of each new ten samples into the buffer/ filters 450 a new low pass filter calculation is performed by multiplying the impulse response (coefficients) by the 519 filter taps. Each filter calculation provides one output sample 35 for respective output buffers 458. In the present embodiment, the output buffers 458 are also continuous FIFO buffers that hold 570 samples of data. The 570 samples provide respective samples or packets (also denoted "snapshot" herein) of samples. The output buffers 458 provide sample data to the 40 statistics operation module 404, saturation transform module **406**, and the pulse rate module **410**, as illustrated in FIG. **6**.

FIG. 9 illustrates additional functional operation details of the statistics module 404. In summary, the statistics module 404 provides first order oximetry calculations and RMS signal values for each of the n wavelengths of light. The statistics module 404 also provides a cross-correlation output which indicates a cross-correlation between the n wavelengths of light.

As represented in FIG. 9, the statistics module 404 receives 50 n packets of samples from the output buffers 458 (not shown) of the sub-sampling module 402 of FIGS. 6 and 8. In one embodiment, the samples include 570 samples at 62.5 Hz which represent the attenuated n wavelengths of light signals with the carrier frequency removed. Each packet is normalized with a log function, as represented in the n log modules 480

The signals are then subjected to bandpass filtering, as represented in the n bandpass filter modules **488**. In the present embodiment, with 570 samples in each packet, the 60 bandpass filters are configured with 301 taps to provide a FIR filter with a linear phase response and little or no distortion. In the present embodiment, the bandpass filter has a pass band from 34 beats/minute to 250 beats/minute. The 301 taps slide over each 570 sample packet in order to obtain 270 filtered 65 samples for each of the n filtered wavelength signal. In one embodiment, the n bandpass filters **488** remove the DC in the

12

signal. However, in another embodiment, addition DC removal operations (not shown) may be provided to assist in DC removal.

After filtering, the last j samples from each packet (each packet now containing 270 samples in the present embodiment) are selected for further processing, as represented in the n select last j samples modules **492**. In one embodiment, j equals 120, and the last 120 samples are selected in the select last j samples modules **492**. In one embodiment, 120 samples are selected because the first 150 samples fall within the settling time for the saturation transfer module **406**. The saturation transfer module **406** processes the same data packets, as further discussed below.

In the present embodiment, saturation equation calculations are performed on each 120-sample packet. In the present embodiment, the saturation calculations are performed in two different ways. For one calculation, the 120-sample packets are processed to obtain each packet's overall RMS value, as represented in the λ_1 through λ_n , RMS modules 496. It should be understood that in the present embodiment there are n such RMS modules, although as few as one RMS module may be used. The resultant RMS values for each of the n wavelengths of light provide input values to a first ratio operation 500, which provides its output as an input to a saturation equation module 502. The ratio operation 500 calculates a ratio of the various signals based upon the multi-wavelength model described above, and illustrated as:

$$r = \frac{\sum_{i=1}^{n} \alpha_{i} N P_{RMS,i}}{\sum_{i=1}^{n} \beta_{i} N P_{RMS,i}}$$

The ratio of the intensity of different light wavelengths may be used to determine the oxygen saturation of the patient. In one embodiment, the ratio is provided to a saturation equation module **502**, which includes a look-up table, a polynomial, or the like. The saturation equation module **502** provides a saturation values at its output **504** based upon the ratio. In another embodiment, the n wavelengths's individual RMS values are also provided as outputs of the statistics operations module **404**

The n 120-sample packets (corresponding to each of the n wavelengths of light) are subjected to a cross-correlation operation as represented in a first cross-correlation module 506. The first cross-correlation module 506 determines if good correlation exists between the various light wavelength signals. This cross correlation is advantageous for detecting defective or otherwise malfunctioning detectors. The cross correlation is also advantageous in detecting when the signal model is satisfied. The signal model of the multi-wavelength physiological monitor is described in greater detail above with respect to FIG. 2, and in greater detail below, with respect to FIG. 10. If correlation becomes too low between the signals, the signal model is not satisfied. In order to determine whether the signal model is satisfied, the normalized cross correlation can be computed by the cross-correlation module **506** for each snapshot of data.

In one embodiment, correlation between any two wavelength signals x_1 and x_2 is determined according to:

$$\frac{\sum_{j} x_{1,j} x_{2,j}}{\sqrt{\sum_{j} x_{1,j}} \sqrt{\sum_{j} x_{2,j}}}$$

For n wavelengths, a cross-correlation matrix, $Corr [x x^T]$, is determined, where $x \in R^n$. In one embodiment, a minimum value of the cross-correlation matrix is determined. The minimum value may be determined by looking for the minimum value within the matrix, or the minimum eigenvalue of the matrix. Other methods may be used, as are well known to those of skill in the art.

If the cross-correlation minimum value is too low, the 15 oximeter **299** provides a warning (e.g., audible, visual, etc.) to the operator. In the present embodiment, if a selected snapshot yields a normalized correlation of less than 0.75, the snapshot does not qualify. Signals which satisfy the signal model will have a correlation greater than the threshold.

In one embodiment, the 120-sample packets are also subjected to a second saturation operation and cross correlation in the same manner as described above, except the 120-sample packets are first divided into equal bins of samples (e.g., five bins of 24 samples each). The RMS, ratio, saturation, and cross correlation operations are performed on a bin-by-bin basis. These operations are represented in the divide into equal bins modules 510 the second RMS modules 514 the second ratio module 518, the second saturation equation module 520, and the second cross-correlation module 522, as illustrated in FIG. 9. In one embodiment, the divide into equal bins modules 510 divide the data into five equal bins. However, the divide into equal bins modules 510 may divide the data into any desirable number of equal bins, for example, 7 bins, 10 bins or 20 bins.

FIG. 10 illustrates additional detail regarding the saturation transform module 406 of FIG. 6. As illustrated in FIG. 10, the saturation transform module 406 includes log module 537, bandpass filter module 538, signal selector module 536, reference generator 530, a multi-variate process estimator 531, a 40 master power curve module 554, a divide into equal bins module 556, and a bin power curve module 533. In another embodiment, the saturation transform module has a reference processor, a correlation canceler, and an integrator to provide a power curve for separate signal coefficients. Reference processors, correlation cancelers, and integrators are well known to those of skill in the art, and are described in U.S. Pat. Nos. 5,632,272 and 5,490,505, both of which are incorporated by reference herein in their entireties.

As depicted in FIG. 10, the saturation transform module 50 406 receives the n packets (one packet for each wavelength of light) from the sub-sampling module 402 (not shown) of FIG. **6**. In one embodiment, each of the n packets contains 570 samples, although other sized packets may be employed. The data stored in the n packets, indicated in FIG. 10 as λ_1 Signal 55 Data, λ_2 Signal Data, ... λ_r , Signal Data, is processed by log module 537. Log module 537 performs a logarithmic function on each of the n packets, similar to the log module 480 of the statistics module 404 described above with reference to FIG. 9. The output of the log module 537 is input to a bandpass filter module 538. In one embodiment, the bandpass filter module 538 performs the same type of filtering as the n bandpass filters 488 of the statistics module 404 described above with reference to FIG. 9. Accordingly, each set of 570 samples subjected to bandpass filtering results in 270 remain- 65 ing samples. The resulting data at the n outputs 542 of the bandpass filter module 538 are, in one embodiment, n vectors

of 270 samples. Each output **542** represents the normalized plethysmographic waveform of the corresponding wavelength of light. The outputs **542** are provided to a signal selector module **536** and a reference generator **530**.

A plurality of possible saturation values (the "saturation axis scan," or SaO_{2_scan} values) are provided to the saturation reference processor 530 in addition to the normalized plethysmographic waveform outputs 542. In the present embodiment, 117 saturation values are provided as the saturation axis scan. In a preferred embodiment, the 117 saturation values range uniformly from a blood oxygen saturation of 34.8 to 105.0. Accordingly, in the present embodiment, the 117 saturation values provide an axis scan for the reference generator 530, which generates a reference signal N_{ref} for use by the multi-variate process estimator 531.

In the present embodiment, the multi-variate process estimator 531 includes a pseudo-inverse, as is known to those of skill in the art. In another embodiment, the multi-variate process estimator 531 is formed by a joint process estimator 20 and a low pass filter. Details of a suitable joint process estimator are provided in U.S. Pat. No. 5,632,272, incorporated by reference herein. However, it will be understood by those of skill in the art that a variety of such processing structures may be utilized. For example, in another embodiment, a correlation canceller, an adaptive linear combiner, an adaptive noise filter, an adaptive noise canceller, an adaptive linear lattice, a neural network, a radial basis, or a voltera are used individually or in combination, instead of or in addition to the Pseudo-Inverse embodiment of the multi-variate process estimator 531. Such processing structures are well known to those of skill in the art, and require no further explanation

It should be understood that the scan values could be chosen to provide higher or lower resolution than 117 scan values. In one embodiment, the scan values are non-uniformly spaced.

As illustrated in FIG. 10, the reference processor 530 accepts the saturation axis scan values as an input and provides a reference signal N_{ref} as an output. However, in another embodiment, saturation axis scan value are provided to a saturation equation module (not shown). In such embodiment, the saturation equation module provides outputs " r_n " that correspond to the plurality of scan value discussed above. The saturation equation simply provides a known ratio that corresponds to the saturation value received as an input based upon data contained within a look-up table, or based upon a known polynomial relationship between the saturation axis scan values and the output " r_n ".

When a saturation equation module is employed, the ratio " r_n " is provided by the saturation equation module as an input to the reference generator **530**, along with the sample packets for each of the n light wavelengths. When a saturation equation module is not employed, as illustrated in FIG. **10**, a plurality of " r_n " values are provided as the saturation axis. In one embodiment, the " r_n " values are represented as $p(SaO_{2_scan})$, a row vector of known constants. The reference generator **530** process the inputs as follows.

The reference generator **530** output N_{ref} is a vector which equals $p(SaO_{2_scan})x$, where x is a vector of the normalized plethysmographic waveforms for each of the n wavelengths of light signals x_i (such as outputs **542**) and $p(SaO_{2_scan})$ is a row vector of known constants.

$$\rho(\mathrm{SaO}_{2_scan}) = f^{-1}(\mathrm{SaO}_{2_scan})b^T - \alpha^T, \rho \epsilon R^{1xn}.$$

The vector x is provided as the outputs **542** illustrated in FIG. **10**. The SaO_{2_scan} values are the "r_n" values provided as the saturation axis, and a and b are known constants defined

based on fitting and/or calibration using experimental data and/or models. This operation is completed for each of the saturation scan values (e.g., 117 possible values in the present embodiment). Accordingly, the resultant data can be described as 117 reference signal vectors of 570 data points each, hereinafter referred to as the reference signal vectors. This data can be stored in an array or any such data structure as is well known to those of skill in the art.

In the present embodiment, as described above, the outputs 542 are also provided to a signal selector module 536. One of the output signals 542 is selected by the signal selector module 536 for further processing by the multi-variate process estimator 531. The selected signal is referred to as X_{sel} . It is understood by those of skill in the art that any one of the output signals 542 may be selected by the signal selector module 536 for further processing.

In one embodiment, the multi-variate process estimator 531 includes a pseudo-inverse, which is used to determine a weight vector w associated with the reference signal N_{ref} and the selected signal. In one embodiment, the multi-variate process estimator 531 creates multiple single-column vectors of time-shifted data from the reference signal N_{ref} . For example, in one embodiment, the multi-variate process estimator 531 creates single-column vectors A, where:

$$A = \begin{bmatrix} N_{ref_1} & N_{ref_7} \\ N_{ref_2} & N_{ref_8} \\ N_{ref_8} & N_{ref_9} \\ N_{ref_4} & N_{ref_10} \\ \vdots & \vdots & \vdots \\ \end{bmatrix} \begin{bmatrix} N_{ref_13} \\ N_{ref_14} \\ N_{ref_15} \\ \vdots \\ \vdots & \vdots \end{bmatrix}...$$

In such embodiment, a pseudo-inverse is determined as $(A^TA)^{-1}A^T$. The weight vector w may then be determined by multiplying the pseudo-inverse by the selected signal (\mathbf{x}_{sel}) from the signal select module **536**. The resulting vector w may be expressed as: $\mathbf{w} = (A^TA)^{-1}A^T\mathbf{x}_{sel}$. The output vectors w of the multi-variate process estimator **531** are provided to a 40 master power curve module **554** and a divide into equal bins module **556**.

The divide into equal bins module **556** divides each of the output vectors into bins having equal numbers of data points. In one embodiment, the divide into equal bins module **556** 45 divides each of the output vectors into five bins, each containing the same number of data points (e.g., with 120 data points per vector, each bin could have 24 data points). Each bin is then provided to a bin power curves module **558**.

In one embodiment, the master power curve module **554** 50 performs a saturation transform as follows. For each output vector, the sum of the squares of the data points is determined. This provides a sum of squares value corresponding to each output vector (each output vector corresponding to one of the saturation scan values). These values provide the basis for a 55 master power curve 555, as further represented in FIG. 11. The horizontal axis of the power curve represents the saturation axis scan values and the vertical axis represents the sum of squares value (or output energy) for each output vector. In one embodiment, as depicted in FIG. 11, each of the sum of 60 squares is plotted with the magnitude of the sum of squares value plotted on the vertical "energy output" axis at the point on the horizontal axis of the corresponding saturation scan value which generated that output vector. This results in a master power curve 558, an example of which is depicted in 65 FIG. 11. This provides a saturation transform in which the spectral content of the attenuated energy is examined by

16

looking at every possible saturation value and examining the output value for the assumed saturation value. As will be understood, where the inputs to the multi-variate process estimator 531 are mostly correlated, the sum of squares for the corresponding output vector of the multi-variate process estimator 531 will be very low. Conversely, where the correlation between the first and second inputs to the multi-variate process estimator 531 are not significantly correlated, the sum of squares of the output vector will be high. Accordingly, where the spectral content of the reference signal and the first input to the multi-variate process estimator 531 are made up mostly of physiological (e.g., movement of venous blood due to respiration) and nonphysiological (e.g., motion induced) noise, the output energy will be low. Where the spectral content of the reference signal and the first input to the multivariate process estimator 531 are not correlated, the output energy will be much higher.

A corresponding transform is completed by the Bin Power Curves module **558**, except a saturation transform power curve is generated for each bin. The resulting power curves are provided as the outputs of the saturation transform module **406**.

In general, in accordance with the signal model embodiment of the present invention, there will be two peaks in the power curves, as depicted in FIG. 11. One peak corresponds to the arterial oxygen saturation of the blood, and one peak corresponds to the venous oxygen concentration of the blood. With reference to the signal model of the present invention, the peak corresponding to the highest saturation value (not 30 necessarily the peak with the greatest magnitude) corresponds to the proportionality coefficient r_a . In other words, the proportionality coefficient r_a corresponds to the ratio which will be measured for the arterial saturation. Similarly, peak that corresponds to the lowest saturation value (not necessarily the peak with the lowest magnitude) will generally correspond to the venous oxygen saturation, which corresponds to the proportionality coefficient r_v in the signal model of the present invention. Therefore, the proportionality coefficient r, will be a ratio corresponding to the venous oxygen saturation.

In order to obtain arterial oxygen saturation, the peak in the power curves corresponding to the highest saturation value could be selected. However, to improve confidence in the value, further processing is completed. FIG. 12 illustrates the operation of the saturation calculation module 408 based upon the output of the saturation transform module 406 and the output of the statistics module 404. As depicted in FIG. 12, the bin power curves and the bin statistics are provided to the saturation calculation module 408. In the present embodiment, the master power curves are not provided to the saturation module 408 but can be displayed for a visual check on system operation. The bin statistics contain the normalized RMS values for each of the wavelengths signals, the seed saturation value, and a value representing the cross-correlation between the various wavelengths's signals, as described in greater detail above with respect to the statistics module 404 of FIG. 9.

The saturation calculation module 408 first determines a plurality of bin attributes as represented by the compute bin attributes module 560. The compute bin attributes module 560 collects a data bin from the information from the bin power curves and the information from the bin statistics. In the present embodiment, this operation involves placing the saturation value of the peak from each power curve corresponding to the highest saturation value in the data bin. In the present embodiment, the selection of the highest peak is performed by first computing the first derivative of the power

curve in question by convolving the power curve with a smoothing differentiator filter function. In the present embodiment, the smoothing differentiator filter function (using a FIR filter) has the following coefficients:

0.014964670230367 0.098294046682706 0.204468276324813 2.717182664241813 5.704485606695227 0.000000000000000-5.704482606695227 -2.717182664241813 -0.204468276324813 -0.098294046682706 -0.014964670230367

This filter performs the differentiation and smoothing. Next, each point in the original power curve in question is evaluated and determined to be a possible peak if the following conditions are met: (1) the point is at least 2% of the maximum value in the power curve; and (2) the value of the 20 where x(n) is the clipped new saturation value, and y(n) is the first derivative changes from greater than zero to less than or equal to zero. For each point that is found to be a possible peak, the neighboring points are examined and the largest of the three points is considered to be the true peak.

The peak width for these selected peaks is also calculated. 25 The peak width of a power curve in question is computed by summing all the points in the power curve and subtracting the product of the minimum value in the power curve and the number of points in the power curve. In the present embodiment, the peak width calculation is applied to each of the bin 30 power curves. The maximum value is selected as the peak width.

In addition, the RMS value from the entire snapshot, the individual wavelengths's RMS values, the seed saturation value for each bin, and the cross correlation between the n 35 wavelengths's signals from the statistics module **404** are also placed in the data bin. The attributes are then used to determine whether the data bin consists of acceptable data, as represented in a bin qualifying logic module 562.

If the correlation is too low, the bin is discarded. If the 40 saturation value of the selected peak for a given bin is lower than the seed saturation for the same bin, the peak is replaced with the seed saturation value. If any wavelength's RMS value is below a threshold, the bins are all discarded, and no saturation value is provided, because the measured signals are 45 considered to be too small to obtain meaningful data. If no bins contain acceptable data, the exception handling module 563 provides a message to the display 336 that the data is erroneous.

If some bins qualify, those bins that qualify as having 50 acceptable data are selected, and those that do not qualify are replaced with the average of the bins that are accepted. Each bin is given a time stamp in order to maintain the time sequence. A voter operation 565 examines each of the bins and selects the three highest saturation values. These values 55 are forwarded to a clip and smooth operation 566.

The clip and smooth operation 566 performs averaging with a low pass filter. The low pass filter provides adjustable smoothing as selected by a select smoothing filter module 568. The select smoothing filter module 568 performs its 60 operation based upon a confidence determination performed by a high confidence test module 570. The high confidence test is an examination of the peak width for the bin power curves. The width of the peaks provides some indication of motion by the patient, wherein wider peaks indicate motion. 65 Therefore, if the peaks are wide, the smoothing filter is slowed down. If peaks are narrow, the smoothing filter speed

18

is increased. Accordingly, the smoothing filter 566 is adjusted based on the confidence level. The output of the clip and smooth module 566 provides the oxygen saturation values in accordance with one embodiment of the present invention.

In one embodiment, the clip and smooth filter 566 takes each new saturation value and compares it to the current saturation value. If the magnitude of the difference is less than 16 (percent oxygen saturation) then the value is pass. Otherwise, if the new saturation value is less than the filtered 10 saturation value, the new saturation value is changed to 16 less than the filtered saturation value. If the new saturation value is greater than the filtered saturation value, then the new saturation value is changed to 16 more than the filtered saturation value.

During high confidence (no motion), the smoothing filter is a simple one-pole or exponential smoothing filter which in one embodiment is computed as follows:

$$y(n)=0.6*x(n)+0.4*y(n-1)$$

filtered saturation value.

During motion condition, a three-pole infinite impulse response (IIR) filter is used. Its characteristics are controlled by three time constants t_a , t_b , and t_c with values of 0.985, 0.900, and 0.94 respectively. The coefficients for a direct form I, IIR filter are computed from these time constants using the following relationships:

$$\begin{split} &a_0 {=} 0 \\ &a_1 {=} t_b {+} (t_c) (t_a {+} t_b) \\ &a_2 {=} (-t_b) (t_c) (t_a {+} t_b {+} (t_c) (t_a)) \\ &a_3 {=} (t_b)^2 (t_c)^2 (t_a) \\ &b_0 {=} 1 {-} t_b {-} (t_c) (t_a {+} (t_e) (t_b)) \\ &b_1 {=} 2 (t_b) (t_c) (t_a {-} 1) \\ &b_2 {=} (t_b) (t_e) (t_b {+} (t_c) (t_a) {-} (t_b) (t_c) (t_a) {-} t_a) \end{split}$$

It is well understood by those of skill in the art that the normalized plethysmographic waveforms of the multi-wavelength physiological monitor may be utilized to determine the pulse rate of the patient. For example, in one embodiment, the normalized plethysmographic waveforms of the multi-wavelength physiological monitor, illustrated as lines λ_1 RMS, λ_2 RMS, ... λ_n RMS in FIG. 9, or the outputs 542 of FIG. 10 may be used to determine the patient's pulse rate. In one embodiment, a Fourier transform is performed on at least one of the normalized plethysmographic waveforms to convert the data of the waveform from the time domain into the frequency domain using methods well known to those of skill in the art. In one embodiment, the first harmonic of the frequency data is identified as the patient's pulse rate.

Other methods of determining pulse rate or heart rate from normalized plethysmographic data is disclosed in U.S. Pat. No. 5,632,272, incorporated by reference in its entirety

While a number of preferred embodiments of the invention and variations thereof have been described in detail, other modifications and methods of using and medical applications for the same will be apparent to those of skill in the art. Accordingly, it should be understood that various applications, modifications, and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.

What is claimed is:

- 1. A physiological monitor for determining blood oxygen saturation of a patient, the physiological monitor comprising: a pulse oximetry sensor comprising:
 - three or more emitters, wherein each emitter is operative 5 to emit light of a different wavelength; and
 - at least one detector adapted to receive light from the three or more emitters after being attenuated by tissue of a medical patient; and

a processor configured to:

compute a ratio based at least in part on three or more data signals, each of the three or more data signals indicative of light from one of the three or more emitters after being attenuated by the tissue, wherein the ratio comprises a quotient of a first weighted sum of the data signals multiplied by a first set of vector coefficients and a second weighted sum of the data signals multiplied by a second set of vector coefficients:

determine blood oxygen saturation based at least in part 20 upon a single blood oxygen saturation curve using said ratio; and

output the oxygen saturation for display to a clinician.

- 2. The physiological monitor of claim 1, wherein the first and second sets of vector coefficients are determined based 25 upon calibration data or fitting of experimental data.
- 3. The physiological monitor of claim 1, wherein the at least one detector provides an output signal based at least in part on the received light and the processor is configured to obtain the three or more data signals from the output signal. ³⁰
- **4**. The physiological monitor of claim **1**, wherein the pulse oximetry sensor is configured to be removably attached to the tissue of the medical patient.
- 5. The physiological monitor of claim 1, wherein the three or more emitters comprise eight light emitting diodes.
- **6**. The physiological monitor of claim **1**, wherein the blood oxygen saturation curve is linear over a range of ratio values, wherein the range of ratio values comprises from about 0.45 to about 1.6.
- 7. The physiological monitor of claim 1, wherein the blood oxygen saturation curve is linear over a range of blood oxygen saturation values, wherein the range of blood oxygen saturation values comprises from about 75% to about 95%.
- **8**. The physiological monitor of claim **1**, wherein the ratio is configured to have reduced tolerance at lower blood oxygen saturation levels compared to a two wavelength blood oxygen saturation system.
- **9**. An apparatus for determining a blood oxygen saturation of a medical patient, the apparatus comprising:

one or more processors configured to:

perform a ratio calculation based at least in part on at least three waveforms, each waveform indicative of attenuation of one of at least three wavelengths of light by tissue, wherein the ratio calculation comprises a quotient of a first weighted sum of the at least three waveforms multiplied by a first set of vector

20

coefficients and a second weighted sum of the at least three waveforms multiplied by a second set of vector coefficients, the first and second sets of vector coefficients determined based upon calibration data;

determine a blood oxygen saturation based at least in part upon a single blood oxygen saturation curve using the ratio; and

output the oxygen saturation for display to a clinician.

- 10. The apparatus of claim 9, wherein said blood oxygen saturation curve is linear over a range of blood oxygen saturation values such that the blood oxygen saturation exhibits higher accuracy at lower blood oxygen saturation levels compared to a two wavelength blood oxygen saturation system.
- 11. The apparatus of claim 10, wherein the range of blood oxygen saturation values comprises about 75% to about 95%.
- 12. The apparatus of claim 9, wherein the ratio is configured to have reduced tolerance at lower blood oxygen saturation levels compared to a two wavelength blood oxygen saturation system.
- 13. A method of determining the blood oxygen saturation of a patient, the method comprising:

under control of a hardware processor,

receiving at least three data signals, each of the data signals corresponding to one of at least three wavelengths of light that have been attenuated by tissue;

calculating a ratio with one or more processors based at least in part on the at least three data signals, wherein the ratio comprises a quotient of a first weighted sum of the at least three data signals multiplied by a first set of vector coefficients and a second weighted sum of the at least three data signals multiplied by a second set of vector coefficients;

determining a blood oxygen saturation based at least in part on a single blood oxygen saturation curve using the ratio; and

- outputting the blood oxygen saturation for display to a clinician.
- 14. The method of claim 13, wherein said blood oxygen saturation curve is linear over a range of blood oxygen saturation values.
- **15**. The method of claim **14**, wherein the range of blood oxygen saturation values comprises about 75% to about 95%.
- 16. The method of claim 13, wherein the ratio exhibits greater linearity over a first range of ratio values compared to a linearity over a second range of ratio values in a two-wavelength blood oxygen saturation system.
- 17. The method of claim 13, further comprising generating a composite signal based at least in part on output signals from at the least three wavelengths of light that have been attenuated by tissue and demodulating said composite signal to yield the at least three data signals.
- 18. The method of claim 13, further comprising determining the at least three data signals by determining an RMS value of each of at least three output signals from the at least three wavelengths of light that have been attenuated by tissue.

* * * * *